

PRODUCT MONOGRAPH

PrTELZIR®

fosamprenavir calcium tablet, 700 mg fosamprenavir

fosamprenavir calcium oral suspension, 50 mg/mL fosamprenavir

Antiretroviral Agent

ViiV Healthcare ULC
8455 route Transcanadienne
Montréal, Quebec
H4S 1Z1

Date of Revision: May 17, 2010

Submission Control No.

©2010 ViiV Healthcare ULC. All Rights Reserved.

®TELZIR is a registered trademark used under license by ViiV Healthcare ULC.

*ViiV Healthcare and the ViiV Healthcare logo are trademarks used under license by ViiV Healthcare ULC.

Table of Contents

PART I: HEALTH PROFESSIONAL INFORMATION.....	3
SUMMARY PRODUCT INFORMATION	3
INDICATIONS AND CLINICAL USE.....	3
CONTRAINDICATIONS	4
WARNINGS AND PRECAUTIONS.....	5
ADVERSE REACTIONS.....	10
DRUG INTERACTIONS	13
DOSAGE AND ADMINISTRATION.....	25
OVERDOSAGE	27
ACTION AND CLINICAL PHARMACOLOGY	27
STORAGE AND STABILITY.....	31
SPECIAL HANDLING INSTRUCTIONS	31
DOSAGE FORMS, COMPOSITION AND PACKAGING	31
PART II: SCIENTIFIC INFORMATION	32
PHARMACEUTICAL INFORMATION.....	32
CLINICAL TRIALS.....	33
DETAILED PHARMACOLOGY	35
MICROBIOLOGY	38
TOXICOLOGY	39
REFERENCES	43
PART III: CONSUMER INFORMATION.....	47

Pr**TELZIR**[®]

fosamprenavir calcium tablet, 700 mg fosamprenavir

fosamprenavir calcium oral suspension, 50 mg/mL fosamprenavir

PART I: HEALTH PROFESSIONAL INFORMATION

SUMMARY PRODUCT INFORMATION

Route of Administration	Dosage Form / Strength	Clinically Relevant Nonmedicinal Ingredients
Oral	Tablet/ 700 mg fosamprenavir	None <i>For a complete listing, see Dosage Forms, Composition and Packaging section</i>
	Suspension/ 50 mg/mL fosamprenavir	methyl parahydroxybenzoate, propyl parahydroxybenzoate. <i>For a complete listing, see Dosage Forms, Composition and Packaging section</i>

INDICATIONS AND CLINICAL USE

TELZIR[®] (fosamprenavir calcium) in combination with low-dose ritonavir is indicated for:

- the treatment of HIV-1 infection in adults and pediatric patients ≥ 6 years old, in combination with other antiretroviral agents.

The following points should be considered when indicating therapy with TELZIR[®] in combination with low-dose ritonavir in protease inhibitor-experienced adults and in pediatric patients ≥ 6 years old:

- The study in protease inhibitor-experienced patients was not large enough to reach a definitive conclusion that TELZIR[®]/ritonavir combination is clinically equivalent to lopinavir/ritonavir combination used as a comparator in the study. No comparative studies were conducted in pediatric patients.

- Once-daily administration of TELZIR[®]/ritonavir combination is not recommended in protease inhibitor-experienced patients or in pediatric patients.
- In protease inhibitor-experienced patients the choice of TELZIR[®] should be based on individual viral resistance and treatment therapy.

CONTRAINDICATIONS

- TELZIR[®] (fosamprenavir calcium) must not be administered concurrently with medicinal products with a narrow therapeutic window that are substrates of cytochrome P450 3A4 (CYP 3A4). Coadministration may result in competitive inhibition of metabolism of these medicinal products and create the potential for serious and/or life-threatening adverse events such as cardiac arrhythmia (for example terfenadine, astemizole, cisapride, pimozide), prolonged sedation or respiratory depression (for example triazolam, midazolam, diazepam, flurazepam) or peripheral vasospasm or ischemia (for example ergot derivatives).
- Ritonavir also inhibits CYP2D6 *in vitro* and *in vivo* but to a lesser extent than CYP3A4. TELZIR[®] in combination with ritonavir should not be coadministered with medicinal products that are highly dependent on CYP2D6 metabolism and for which elevated plasma concentrations are associated with serious and/or life-threatening results. These medicinal products include flecainide and propafenone (please refer to the full prescribing information for ritonavir for further details).
- TELZIR[®] should not be given with rifampin. Rifampin reduces trough plasma concentrations of amprenavir by approximately 92% (see DRUG INTERACTIONS section).
- TELZIR[®] is contraindicated in patients with previously demonstrated clinically significant hypersensitivity (e.g. Stevens Johnson Syndrome) to fosamprenavir calcium, amprenavir, ritonavir, or to any of the excipients of the products. For a complete listing, see the DOSAGE FORMS, COMPOSITION AND PACKAGING section of the Product Monograph.

Table 1 Drugs that are Contraindicated with TELZIR®

Drug Class	Drugs
Ergot Derivatives	Dihydroergotamine, ergonovine, ergotamine, methylergotamine
GI Motility agents	Cisapride*
Antihistamine	Astemizole*, terfenadine*
Antiarrhythmic	flecainide, propafenone
Neuroleptic	Pimozide
Sedatives/Hypnotics	Midazolam, triazolam, diazepam, flurazepam

* products no longer marketed in Canada

WARNINGS AND PRECAUTIONS

General

Serious and/or life-threatening drug interactions could occur between TELZIR® (fosamprenavir calcium) and amiodarone, lidocaine (systemic), halofantrine, tricyclic antidepressants, quinidine or warfarin (monitor International Normalized Ratio). Concentration monitoring of these agents is recommended if these agents are used concomitantly with TELZIR®. Severe and life-threatening skin reactions, including Stevens-Johnson syndrome, were reported in less than 1% of subjects included in the clinical development programme. The TELZIR®/ritonavir combination should be permanently discontinued in case of severe rash, or in case of rash of moderate intensity with systemic or mucosal symptoms (see ADVERSE REACTIONS section).

Rifampin should not be used in combination with TELZIR® since it reduces the C_{min} of amprenavir by 92% and AUC by 82% (see CONTRAINDICATIONS and DRUG INTERACTIONS sections).

Phenobarbital, phenytoin, carbamazepine and dexamethasone may decrease amprenavir concentrations (see DRUG INTERACTIONS section).

HMG-CoA reductase inhibitors (statins) may interact with protease inhibitors and increase the risk of myopathy including rhabdomyolysis. Concomitant use of protease inhibitors with lovastatin or simvastatin is not recommended. Other HMG-CoA reductase inhibitors (statins), may also interact with protease inhibitors.

Use the lowest possible dose of atorvastatin with careful monitoring or consider the use of pravastatin or fluvastatin as alternative HMG-CoA reductase inhibitors in combination with TELZIR® (see DRUG INTERACTIONS section).

The concomitant use of TELZIR[®]/ritonavir with lopinavir/ritonavir is not recommended because of significant pharmacokinetic interactions (see DRUG INTERACTIONS section).

Coadministration of protease inhibitors with PDE5 inhibitors is expected to substantially increase PDE5 inhibitor concentrations and may result in an increase in PDE5 inhibitor-associated adverse events, including hypotension, syncope, visual changes, and priapism (see DRUG INTERACTIONS section and the complete prescribing information for PDE5 inhibitors). Concomitant use of PDE5 inhibitors (e.g. tadalafil, vardenafil or sildenafil) in patients receiving TELZIR[®] is not recommended (see DRUG INTERACTIONS section).

Concomitant use of St. John's Wort (*Hypericum perforatum*) or St. John's Wort-containing products and TELZIR[®] is not recommended. Coadministration of St. John's Wort with protease inhibitors, including TELZIR[®], is expected to substantially decrease protease inhibitor concentrations and may result in suboptimal levels of amprenavir and lead to loss of virologic response and possible resistance to amprenavir or the class of protease inhibitors (see DRUG INTERACTIONS section).

Although the isozyme(s) responsible for bepridil metabolism has (have) not been elucidated, the metabolic pathways primarily responsible for bepridil metabolism are mediated by the CYP450 enzyme system. Because amprenavir and ritonavir are inhibitors of the CYP3A4 isozyme, the CYP450 isozyme most commonly responsible for drug metabolism, and because increased plasma bepridil exposure may increase the risk of life-threatening arrhythmia, caution is warranted when TELZIR[®] and ritonavir are coadministered with bepridil (see DRUG INTERACTIONS section).

Coadministration of amprenavir with rifabutin results in a 200% increase in rifabutin plasma concentrations (AUC). When ritonavir is coadministered with TELZIR[®], a larger increase in rifabutin concentrations is expected. A reduction of rifabutin dosage of at least 75% of the recommended dose is recommended when administered with TELZIR[®] and ritonavir and patients should be clinically monitored (see DRUG INTERACTIONS section).

The TELZIR[®] oral suspension contains propyl and methyl parahydroxybenzoate. These products may cause an allergic reaction in some individuals. This reaction may be delayed.

Use of TELZIR[®] with ritonavir at higher than approved dosages has resulted in elevated transaminase levels in some subjects and is not recommended for use (see DOSAGE AND ADMINISTRATION section).

Sulphonamide Allergies

TELZIR[®] should be used with caution in patients with a known sulphonamide allergy. Fosamprenavir calcium contains a sulphonamide moiety. The potential for cross-sensitivity between drugs in the sulphonamide class and TELZIR[®] is unknown. In the clinical studies where patients received TELZIR[®] as the sole protease inhibitor or in combination with low-dose ritonavir, the incidence of rash was similar in patients with a history of sulphonamide allergy as compared to those who did not have a sulphonamide allergy.

Contraceptives

There may be an increased risk of clinically significant hepatic transaminase elevations and hormonal levels may be altered with co-administration of fosamprenavir, ritonavir and oral contraceptives. Therefore, concomitant use of fosamprenavir, ritonavir and oral contraceptives is not recommended and alternate methods of non-hormonal contraception are recommended for women of childbearing potential (see DRUG INTERACTIONS section).

Hormonal Replacement Therapies

No data are available on the co-administration of fosamprenavir and ritonavir with estrogens and/or progestogens when used as hormonal replacement therapies. The efficacy and safety of these therapies with fosamprenavir and ritonavir has not been established.

Carcinogenesis and Mutagenesis

Data from long-term carcinogenicity studies with amprenavir has revealed histopathological evidence for hepatocellular adenomas in males at the high dose of 500 mg/kg/day in mice or 750 mg/kg/day in rats, and altered hepatocellular foci were seen in male mice only at doses of 275 and 500 mg/kg/day. The clinical relevance of these findings is unknown (see TOXICOLOGY, Carcinogenicity section).

Endocrine and Metabolism

New-onset diabetes mellitus, exacerbation of pre-existing diabetes mellitus and hyperglycemia have been reported during post-marketing surveillance in HIV-infected patients receiving protease inhibitor therapy. Some required either initiation or dose adjustments of insulin or oral hypoglycemic agents for treatment of these events. In some cases diabetic ketoacidosis has occurred. In those patients who discontinued protease inhibitor therapy, hyperglycemia persisted in some cases. Because these events have been reported voluntarily during clinical practice, estimates of frequency cannot be made and causal relationship between protease inhibitor therapy and these events has not been established (see ADVERSE REACTIONS section).

Fat Redistribution

Redistribution/accumulation of body fat, including central obesity, dorsocervical fat enlargement ("buffalo hump"), peripheral wasting, breast enlargement, and "cushingoid appearance," have been observed in patients receiving antiretroviral therapies. The mechanism and long-term consequences of these events are currently unknown. A causal relationship has not been established (see ADVERSE REACTIONS section).

Lipid Elevations

Treatment with TELZIR[®] plus ritonavir has resulted in increases in the concentration of triglycerides and cholesterol (see ADVERSE REACTIONS section). Triglycerides and cholesterol testing should be performed prior to initiating therapy with TELZIR[®] and at periodic intervals during therapy. Lipid disorders should be managed as clinically appropriate (see DRUG INTERACTIONS section).

Hematologic

Acute hemolytic anemia has been reported in a patient treated with TELZIR[®].

Patients with Hemophilia

There have been reports of increased bleeding, including spontaneous skin hematomas and hemarthroses, in hemophiliac patients type A and B treated with protease inhibitors. In some patients additional factor VIII was given. In more than half of the reported cases, treatment with protease inhibitors was continued or reintroduced if treatment had been discontinued. A causal relationship has been evoked, although the mechanism of action has not been elucidated. Hemophiliac patients should therefore be made aware of the possibility of increased bleeding (see ADVERSE REACTIONS section).

Hepatic/Biliary/Pancreatic

Amprenavir and ritonavir are principally metabolized by the liver. TELZIR[®] with ritonavir at higher than recommended doses may result in transaminase elevations and should not be used. TELZIR[®] with ritonavir should be used with caution and at reduced doses in adults with mild, moderate or severe hepatic impairment because amprenavir concentrations may be increased (see CLINICAL TRIALS and DOSAGE AND ADMINISTRATION sections).

Patients with underlying hepatitis B or C or marked elevations in transaminases prior to treatment may be at increased risk of developing or worsening of transaminase elevations. Appropriate laboratory testing should be conducted prior to initiating therapy and at periodic intervals during treatment.

Immune

Immune Reconstitution: During the initial phase of treatment, patients responding to antiretroviral therapy may develop an inflammatory response to indolent or residual opportunistic infections (such as MAC, CMV, PCP and TB), which may necessitate further evaluation and treatment.

Renal

The safety and efficacy of TELZIR[®] have not been studied in patients with renal impairment. Since the renal clearance of amprenavir and ritonavir is negligible, increased plasma concentrations are not expected in patients with renal impairment. Because amprenavir and ritonavir are highly protein bound, it is unlikely that hemodialysis or peritoneal dialysis will significantly remove them (see ACTIONS AND CLINICAL PHARMACOLOGY section).

Sensitivity/Resistance

Resistance/Cross-Resistance

Because the potential for HIV cross-resistance among protease inhibitors has not been fully explored, it is unknown what effect therapy with TELZIR[®] will have on the activity of subsequently administered protease inhibitors. TELZIR[®] has been studied in patients who have experienced treatment failure with protease inhibitors (see DETAILED PHARMACOLOGY: Description of Clinical Studies section).

Skin

Severe and life-threatening skin reactions, including Stevens-Johnson Syndrome, have occurred in patients treated with amprenavir (see ADVERSE REACTIONS).

Special Populations

Pregnant Women

There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies are not always predictive of human response; therefore, administration of TELZIR[®] in pregnancy should be considered only if the benefit to the mother outweighs the possible risk to the fetus.

Antiretroviral Pregnancy Registry: To monitor maternal-fetal outcomes of pregnant women exposed to TELZIR[®], an Antiretroviral Pregnancy Registry has been established. Physicians are encouraged to register patients by calling ViiV Healthcare ULC's Drug Safety Department (1-877-393-8448).

Nursing Women

Although it is not known if amprenavir is excreted in human milk, amprenavir is secreted into the milk of lactating rats. Because of both the potential for HIV transmission and possible adverse effects of amprenavir, mothers should be instructed not to breastfeed if they are receiving TELZIR[®].

Pediatrics

No pharmacokinetics, safety or efficacy data are available for pediatric patients < 2 years old (see DOSAGE AND ADMINISTRATION section).

Geriatrics

The pharmacokinetics of TELZIR[®] in combination with ritonavir has not been studied in patients over 65 years of age. When treating elderly patients, consideration should be given to potential hepatic, renal or cardiac dysfunction, concomitant disease or other drug therapy (see DOSAGE AND ADMINISTRATION and ACTIONS AND CLINICAL PHARMACOLOGY sections).

ADVERSE REACTIONS

Adverse Drug Reaction Overview

New onset of diabetes mellitus, hyperglycemia or exacerbations of existing diabetes mellitus has been reported in patients receiving antiretroviral protease inhibitors (see WARNINGS AND PRECAUTIONS section).

An increase in CPK, myalgia, myositis, and rarely, rhabdomyolysis, has been reported with protease inhibitors, more specifically in association with nucleoside analogues.

There have been reports of increased spontaneous bleeding in hemophiliac patients receiving antiretroviral protease inhibitors (see WARNINGS AND PRECAUTIONS section).

Clinical Trial Adverse Drug Reactions

Because clinical trials are conducted under very specific conditions the adverse reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse drug reaction information from clinical trials is useful for identifying drug-related adverse events and for approximating rates.

Studies in Adults:

The safety of TELZIR[®] (fosamprenavir calcium) in combination with ritonavir has been studied in adults in controlled clinical trials, in combination with various other antiretroviral agents. The most frequently (> 5% of adult subjects treated) reported undesirable effects were gastrointestinal events (nausea, diarrhea, abdominal pain and vomiting), headache and rash. Most undesirable effects associated with TELZIR[®]/ritonavir combination therapies were mild to moderate in severity, early in onset and rarely treatment limiting. For many of these events, it is unclear whether they are related to the TELZIR[®]/ritonavir combination, to concomitant treatment used in the management of HIV disease or to the disease process.

Adverse events are listed by *MedDRA* system, organ class and frequency category. Frequencies are defined as Common ($\geq 1\%$ to $< 10\%$), Uncommon ($\geq 0.1\%$ to $< 1\%$) and Rare ($\geq 0.01\%$ to $< 0.1\%$).

Frequency categories for the events below have been based on clinical trials.

Most of the adverse events below come from two large clinical trials in adults. The most frequent clinical adverse events related to study drugs, of at least moderate intensity (Grade 2 or more) and occurring in at least 2% of subjects treated with the TELZIR[®]/ritonavir combinations are included.

Table 2 Clinical Trial Adverse Drug Reactions

Frequency	Body System	Adverse Drug Reaction
Common	Gastrointestinal disorders	abdominal pain, diarrhea, flatulence, nausea and vomiting
	General disorders	fatigue
	Metabolic and nutrition disorders	hypertriglyceridemia
	Nervous system disorders	headache, oral paraesthesia
	Skin and subcutaneous tissue disorders	rash
Uncommon	Urogenital disorders	Nephrolithiasis
Rare	Skin and subcutaneous tissue disorders	Stevens Johnson syndrome, angioedema

The adverse event profile was similar across all the respective adult studies: antiretroviral-naïve (APV30002, n = 322) and PI-experienced (once-or twice-daily dosing, APV30003 n = 105 and n = 107 respectively), with the exception of flatulence. This was only reported at a frequency of > 2% in study APV30003 (PI-experienced subjects, TELZIR[®]/ritonavir 700/100 mg twice daily).

In antiretroviral-naïve patients (APV30002) receiving TELZIR[®]/ritonavir in combination with abacavir and lamivudine, drug hypersensitivity was commonly reported. All cases were reported as possibly related to abacavir. In cases of reported drug hypersensitivity, abacavir was discontinued and an alternative antiretroviral drug substituted. Few patients withdrew from the study due to these events.

Erythematous or maculopapular cutaneous eruptions, with or without pruritus, may occur during therapy. The rash generally will resolve spontaneously without the necessity of discontinuing of treatment with the TELZIR[®]/ritonavir combination.

Severe or life threatening rash, including Stevens Johnson syndrome, has been reported in less than 1% of subjects included in the clinical studies of TELZIR[®]. Treatment with TELZIR[®] should be discontinued for severe or life-threatening rashes and for moderate rashes accompanied by systemic symptoms or mucosal signs.

In some patients, fat redistribution, including a decrease in subcutaneous peripheral fat, an increase in intra-abdominal fat, breast hypertrophy and an accumulation of retrocervical fat (“buffalo hump”) has been reported with antiretroviral regimen containing a protease inhibitor. Metabolic abnormalities including hypertriglyceridemia, hypercholesterolemia, resistance to insulin and hyperglycemia have also been reported with protease inhibitor-containing regimens.

Studies in Pediatric Patients:

TELZIR[®] with and without ritonavir was studied in 144 pediatric patients 2 to 18 years of age in 2 open-label studies. Safety information was obtained from 75 pediatric patients receiving TELZIR[®] twice daily with or without ritonavir.

All adverse events, regardless of causality, all drug-related adverse events, and all laboratory events occurred with similar frequency in pediatrics as compared to adults, with the exception of vomiting. Vomiting, regardless of causality, occurred more frequently among pediatric patients receiving TELZIR[®] twice daily with ritonavir (30% in patients between 2 and 18 years old) and without ritonavir (56%, in patients between 2 and 5 years old) as compared to adults receiving TELZIR[®] twice daily with ritonavir (10%) and without ritonavir (16%). The median duration of drug-related vomiting episodes was 1 day (range 1 to 62 days). Vomiting required the permanent discontinuation of treatment in 1 pediatric patient and temporary discontinuation of treatment in 3 pediatric patients, all of whom were receiving TELZIR[®] twice daily with ritonavir.

Abnormal Hematologic and Clinical Chemistry findings

Clinical laboratory abnormalities (Grade 3 or 4) potentially related to treatment with TELZIR[®] in combination with ritonavir and reported in greater than or equal to 2% of adult subjects are summarized in Table 3.

Table 3 Clinical laboratory abnormalities (Grade 3 or 4) potentially related to treatment with TELZIR[®] in combination with ritonavir and reported in greater than or equal to 2% of adult subjects.

Clinical Abnormality (increased levels)	APV30002 (naïve patients)	APV30003 (experienced patients)
ALT	8%	5%
AST	6%	4%
Serum Lipase	6%	4%
Triglycerides	6%	6%

Grade 3 /4 neutropenia was documented in a higher proportion of pediatric subjects in Study APV20003 (20%) than in Study APV29005 (4%). The reason for the amount of neutropenia seen in APV20003 is unclear, and confounded by several factors (concomitant medications, compromised sample integrity, and changes in the toxicity grading scale). In APV29005, the rate of neutropenia was comparable to that seen in the adult population.

Post-Market Adverse Drug Reactions

Body as a Whole: Redistribution/accumulation of body fat (see WARNINGS AND PRECAUTIONS: Fat redistribution section).

Cardiovascular: Myocardial infarction

Endocrine and Metabolism: New-onset diabetes mellitus, exacerbation of pre-existing diabetes mellitus, hyperglycemia and hypercholesterolemia have been reported during post-marketing surveillance in HIV-infected patients receiving protease inhibitor therapy (see WARNINGS AND PRECAUTIONS: Endocrine and Metabolism section).

Urogenital: Nephrolithiasis

Skin and Subcutaneous Tissue Disorders: Stevens Johnson Syndrome and angioedema.

DRUG INTERACTIONS

Overview

When TELZIR[®] (fosamprenavir calcium) and ritonavir are coadministered, the ritonavir metabolic drug interaction profile may predominate because ritonavir is a more potent CYP3A4 inhibitor. The full prescribing information for ritonavir must therefore be consulted prior to initiation of therapy with TELZIR[®] and ritonavir.

Interaction studies have only been performed in adults.

Amprenavir, the active metabolite of TELZIR[®], is metabolized in the liver by the cytochrome P450 enzyme system. Amprenavir inhibits CYP3A4. Caution should be used when coadministering medications that are substrates, inhibitors, or inducers of CYP3A4. TELZIR[®] should not be administered concurrently with medications with a narrow therapeutic window that are substrates of CYP3A4. Ritonavir also inhibits CYP2D6 and induces CYP3A4, CYP1A2, CYP2C9 and glucuronosyl transferase. Therefore, the combination of ritonavir with TELZIR[®] may result in increased plasma concentrations of medicinal products that are primarily metabolized by CYP2D6. There are also other agents that may result in serious and/or life-threatening drug interactions (see CONTRAINDICATIONS section).

Drug-Drug Interactions

Drug interaction studies were performed with TELZIR[®] tablets and amprenavir formulations. The effects of coadministration of amprenavir on the AUC, C_{max}, and C_{min} are summarized in Table 4. The effects of TELZIR[®] on the pharmacokinetics of other drugs are summarized in Table 5.

Table 4 Drug Interactions: Pharmacokinetic Parameters for Amprenavir After Administration of TELZIR® (fosamprenavir calcium) in the Presence of Coadministered Drug

Coadministered Drug(s) and Dose(s)	Dose of TELZIR®*	n	% Change in Amprenavir Pharmacokinetic Parameters (90% CI)		
			C _{max}	AUC	C _{min}
Antacid (MAALOX TC®) 30 mL single dose	1,400 mg single dose	30	↓35 (↓24 to ↓42)	↓18 (↓9 to ↓26)	↑14 (↓7 to ↑39)
Atazanavir 300 mg q.d. for 10 days	700 mg b.i.d plus ritonavir 100 mg b.i.d. for 10 days	22	↔	↔	↔
Atorvastatin 10 mg q.d. for 4 days	1,400 mg b.i.d. for 2 weeks	16	↓18 (↓34 to ↑1)	↓27 (↓41 to ↓12)	↓12 (↓27 to ↓6)
Atorvastatin 10 mg q.d. for 4 days	700 mg b.i.d. plus ritonavir 100 mg b.i.d. for 2 weeks	16	↔	↔	↔
Efavirenz 600 mg q.d. for 2 weeks	1,400 mg q.d. plus ritonavir 200 mg q.d. for 2 weeks	16	↔	↓13 (↓30 to ↑7)	↓36 (↓8 to ↓56)
Efavirenz 600 mg q.d. plus Ritonavir 100 mg q.d. for 2 weeks	1,400 mg q.d. plus ritonavir 200 mg q.d. for 2 weeks	16	↑18 (↑1 to ↑38)	↑11 (0 to ↑24)	↔
Efavirenz 600 mg q.d. for 2 weeks	700 mg b.i.d. plus ritonavir 100 mg b.i.d. for 2 weeks	16	↔	↔	↓17 (↓4 to ↓29)
Ethinyl estradiol/norethisterone 0.035 mg/0.5 mg q.d. for 21 days	700 mg b.i.d. plus ritonavir 100 mg b.i.d. for 21 days	23	↔ ^a	↔ ^a	↔ ^a
Lopinavir/ritonavir 533 mg/133 mg b.i.d.	1,400 mg b.i.d. for 2 weeks	18	↓13	↓26	↓42
Lopinavir/ritonavir 400 mg/100 mg b.i.d. for 2 weeks	700 mg b.i.d. plus ritonavir 100 mg b.i.d. for 2 weeks	18	↓58 (↓42 to ↓70)	↓63 (↓51 to ↓72)	↓65 (↓54 to ↓73)
Methadone 70 to 120 mg q.d. for 2 weeks	700 mg b.i.d. plus ritonavir 100 mg b.i.d. for 2 weeks	19	↔ ^a	↔ ^a	↔ ^a
Phenytoin 300 mg q.d. for 10 days	700 mg b.i.d. plus ritonavir 100 mg b.i.d. for 10 days	13	↔	↑20 (↑8 to ↑34)	↑19 (↑6 to ↑33)
Ranitidine 300 mg single dose	1,400 mg single dose	30	↓51 (↓43 to ↓58)	↓30 (↓22 to ↓37)	↔ (↓19 to ↑21)
Nevirapine 200 mg b.i.d for 14 days ^b	700 mg b.i.d plus ritonavir 100 mg b.i.d for 14 days	17	↔	↓11 (↓23 to ↑3)	↓19 (↓32 to ↓4)

*concomitant medication is also shown in this column where appropriate

↑ = Increase; ↓ = Decrease; ↔ = No change (↑ or ↓ < 10%).

^a = compared with historical control.

^b = patients were receiving nevirapine for at least 12 weeks prior to study.

Table 5 Drug Interactions: Pharmacokinetic Parameters for Coadministered Drug in the Presence of Amprenavir After Administration of TELZIR[®] (fosamprenavir calcium)

Coadministered Drugs and Dose(s)	Dose of TELZIR [®] *	n	% Change in Pharmacokinetic Parameters of Coadministered Drug (90% CI)		
			C _{max}	AUC	C _{min}
Atazanavir 300 mg q.d. for 10 days	700 mg b.i.d. plus ritonavir 100 mg b.i.d. for 10 days	21	↓24**	↓22**	↔**
Ritonavir 100 mg b.i.d. for 10 days	700 mg b.i.d. plus atazanavir 300 mg q.d. for 10 days	22	↑96 [§]	↑93 [§]	↑37 [§]
Atorvastatin 10 mg q.d. for 4 days	1,400 mg b.i.d. for 2 weeks	16	↑304 (↑205 to ↑437)	↑130 (↑100 to ↑164)	↓10 (↓27 to ↑12)
Atorvastatin 10 mg q.d. for 4 days	700 mg b.i.d. plus ritonavir 100 mg b.i.d. for 2 weeks	16	↑184 (↑126 to ↑257)	↑153 (↑115 to ↑199)	↑73 (↑45 to ↑108)
Ethinyl estradiol*** 0.035 mg q.d. for 21 days	700 mg b.i.d. plus ritonavir 100 mg b.i.d. for 21 days	25	↓28 (↓21 to ↓35)	↓37 (↓30 to ↓42)	ND
Lopinavir/ritonavir [†] 533 mg/133 mg b.i.d. for 2 weeks	1,400 mg b.i.d. for 2 weeks	18	↔	↔	↔
Lopinavir/ritonavir [†] 400 mg/100 mg b.i.d. for 2 weeks	700 mg b.i.d. plus ritonavir 100 mg b.i.d. for 2 weeks	18	↑30 (↓15 to ↑47)	↑37 (↓20 to ↑55)	↑52 (↓28 to ↑82)
Methadone 70 to 120 mg q.d. for 2 weeks	700 mg b.i.d. plus ritonavir 100 mg b.i.d. for 2 weeks	19	R-Methadone (active)		
			↓21 ^a (↓30 to ↓12)	↓18 ^a (↓27 to ↓8)	↓11 ^a (↓21 to ↑1)
			S-Methadone (inactive)		
			↓43 ^a (↓49 to ↓37)	↓43 ^a (↓50 to ↓36)	↓41 ^a (↓49 to ↓31)
Norethisterone*** 0.5 mg q.d. for 21 days	700 mg b.i.d. plus ritonavir 100 mg b.i.d. for 21 days	25	↓38 (↓32 to ↓44)	↓34 (↓30 to ↓37)	↓26 (↓20 to ↓32)
Phenytoin 300 mg q.d. for 10 days	700 mg b.i.d. plus ritonavir 100 mg b.i.d. for 10 days	14	↓20 (↓12 to ↓27)	↓22 (↓17 to ↓27)	↓29 (↓23 to ↓34)
Nevirapine 200 mg b.i.d. for 2 weeks*	700 mg b.i.d. plus ritonavir 100 mg b.i.d. for 2 weeks	17	↑13 (↑3 to ↑24)	↑14 (↑5 to ↑24)	↑22 (↑9 to ↑35)

*concomitant medication is also shown in this column where appropriate

**relative to values obtained from atazanavir (300 mg once daily) plus ritonavir (100 mg once daily)

[†] data represent lopinavir concentrations

***administered as a combination oral contraceptive tablet: ethinyl estradiol 0.035 mg/norethisterone 0.5 mg.

↑ = Increase; ↓ = Decrease; ↔ = No change (↑ or ↓ < 10%).

ND=interaction cannot be determined as C_{min} was below the lower limit of quantification.

^a = dose normalized to 100 mg methadone. The unbound concentration of the active moiety, R-methadone, was unchanged.

[§] compared to coadministration of fosamprenavir 700 mg twice daily plus 100 mg twice daily.

* patients were receiving nevirapine for at least 12 weeks prior to study.

Although interactions with TELZIR[®] to the following drugs have not been studied, since fosamprenavir calcium is metabolized to the active moiety, amprenavir, the information is included for reference in Table 6.

Table 6 Drug Interactions: Pharmacokinetic Parameters after Administration of Amprenavir

Pharmacokinetic Parameters for Amprenavir in the Presence of the Coadministered Drug			Coadministered Drug	Pharmacokinetic Parameters for Coadministered Drug in the Presence of Amprenavir		
C _{max}	AUC	C _{min}		C _{max}	AUC	C _{min}
↑47%	↑29%	↑27%	Abacavir	↔	↔	↔
↑15%	↑18%	↑39%	Clarithromycin	↓10%	↔	↔
↑18%	↑33	↑25%	Indinavir	↓22%	↓38	↓27%
↓16%	↑31	NA	Ketoconazole (sd)	↑19%	↑44%	NA
↔	↔	NA	Lamivudine (sd)	↔	↔	NA
↓14%	↔	↑189%	Nelfinavir	↑12%	↑15%	↑14%
↔	↓15%	↓15%	Rifabutin	↑119%	↑193%	↑271%
↓70%	↓82%	↓92%	Rifampin	↔	↔	ND
↓37%	↓32%	↓14%	Saquinavir*	↑21%	↓19%	↓48%
↔	↑13%	NA	Zidovudine (sd)	↑40%	↑31%	NA
NA ⁽¹⁾	NA ⁽¹⁾	NA ⁽¹⁾	R-methadone (active)	↓25%	↓13%	↔
NA ⁽¹⁾	NA ⁽¹⁾	NA ⁽¹⁾	S-methadone (inactive)	↓48%	↓40%	↓23%
↔	↓22%	↓20%	Ethinyl estradiol	↔	↔	↑32%
			norethindrone	↔	↑18%	↑45%

↑ = Increase; ↓ = Decrease; ↔ = no significant change; NA = Not applicable; sd = Single-dose study

ND = Interaction cannot be determined as C_{min} was below lower limit of quantitation

⁽¹⁾ = see Other Possible Interactions, Methadone

* = (soft gelatine capsules)

The following drug interaction data was obtained in adults.

Table 7 Established or Potential Drug-Drug Interactions

Concomitant Class Name: Drug Name	Effect on Concentration of Amprenavir or Concomitant Drug	Clinical Comment
Antiretroviral Agents		
HIV Protease Inhibitors (see Tables 4 and 5)		
Lopinavir/ritonavir	↓ Lopinavir ↓ Amprenavir	An increased rate of adverse events has been reported with coadministration of these medications: lopinavir and ritonavir. Appropriate doses of the combinations with respect to safety and efficacy have not been established.
Atazanavir/ritonavir	↓ Atazanavir	Coadministration of fosamprenavir (700 mg twice daily) plus ritonavir (100 mg twice daily) with atazanavir (300 mg once daily) for 10 days had no effect on steady state plasma amprenavir pharmacokinetics. Atazanavir plasma AUC(0-τ) decreased by 22%, C _{max} by 24% and C _τ remained unchanged relative to values obtained from atazanavir (300 mg once daily) plus ritonavir (100 mg once daily).
	↑ Ritonavir	Coadministration of fosamprenavir 700 mg twice daily plus ritonavir 100 mg twice daily with atazanavir 300 mg once daily increased plasma ritonavir AUC (0-τ) by 93%, C _{max} by 96%, and C _τ by 37%, compared to coadministration of fosamprenavir 700 mg twice daily plus ritonavir 100 mg twice daily.
Nucleoside analogue reverse transcriptase inhibitors (NRTIs)		
Abacavir	No effect	There were no clinically significant effects of amprenavir, administered as AGENERASE [®] on abacavir in subjects receiving both agents based on historical data.
Tenofovir		In a phase III clinical trial (APV 30003), plasma amprenavir trough concentrations were similar for subjects receiving tenofovir disoproxil fumarate in combination with TELZIR [®] and ritonavir as compared to subjects not receiving tenofovir.

Concomitant Class Name: Drug Name	Effect on Concentration of Amprenavir or Concomitant Drug	Clinical Comment
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)		
Efavirenz	↓ Amprenavir	<p>An additional 100 mg/day (300 mg total) of ritonavir is recommended when efavirenz is administered with TELZIR[®] plus ritonavir once daily.</p> <p>No change in the ritonavir dose is required when efavirenz is administered with TELZIR[®] plus ritonavir twice daily.</p>
Nevirapine	↓ Amprenavir	<p>The AUC and C_{min} of amprenavir were decreased by 11% and 19% respectively, with C_{max} unchanged when fosamprenavir (700 mg twice daily) plus ritonavir (100 mg twice daily) was given concomitantly with nevirapine (200 mg twice daily). The AUC, C_{max} and C_{min} of nevirapine were increased by 14%, 13% and 22% respectively. Therefore, if nevirapine is given in combination with fosamprenavir (700 mg twice daily) plus ritonavir (100 mg twice daily), no dose adjustment is necessary. The fosamprenavir with ritonavir once daily regimen has not been studied.</p>
Delavirdine	↓ Delavirdine	<p>Appropriate doses of the combination of TELZIR[®] plus ritonavir and delavirdine have not been established.</p> <p>Coadministration of fosamprenavir and delavirdine is not recommended because significant reductions in delavirdine concentrations are observed.</p>
Antimalarial Agents		
Halofantrine	↑ Halofantrine	<p>Coadministration of fosamprenavir with halofantrine is not recommended as halofantrine concentrations may be increased, potentially increasing the risk of serious adverse effects such as cardiac arrhythmia. Concomitant use is not recommended.</p>

Concomitant Class Name: Drug Name	Effect on Concentration of Amprenavir or Concomitant Drug	Clinical Comment
Antiarrhythmics		
Amiodarone Bepidil Lidocaine (systemic) Quinidine	↑ Antiarrhythmics	Use with caution. Increased exposure may be associated with life-threatening reactions such as cardiac arrhythmias. Therapeutic concentration monitoring, if available, is recommended for antiarrhythmics.
Antibiotics/Antifungals		
Clarithromycin	↑ Clarithromycin	Ritonavir increases plasma concentrations of clarithromycin. A reduction in the clarithromycin dose should be considered when coadministered with fosamprenavir calcium and ritonavir in patients with renal impairment.
Dapsone Erythromycin	↑ Dapsone ↑ Erythromycin	The plasma concentrations of these medicinal products may be increased when coadministered with TELZIR®. No pharmacokinetic study has been performed with fosamprenavir calcium in combination with erythromycin or dapsone; however, the plasma concentrations of these medicinal products may be increased when coadministered with TELZIR®. Erythromycin may also increase amprenavir serum concentration.
Itraconazole Ketoconazole	↑ Itraconazole ↑ Ketoconazole	Coadministration may increase plasma concentrations of either drug. Amprenavir and ritonavir both increase plasma concentrations of ketoconazole and are expected to increase itraconazole concentrations. Itraconazole can increase amprenavir concentrations. High doses of ketoconazole and itraconazole (> 200 mg/day) should not be used concomitantly with fosamprenavir calcium and ritonavir without assessing the risk/benefit ratio and increased monitoring for adverse events due to ketoconazole and itraconazole.
Rifampin	↓ Amprenavir	The pharmacokinetic parameters of amprenavir are affected when both drugs are administered in combination. Rifampin should not be used in combination with fosamprenavir calcium since it reduced C _{min} of amprenavir by 92% and the AUC by 82% (see CONTRAINDICATIONS section).
Rifabutin	↓ Amprenavir ↑ Rifabutin	The pharmacokinetic parameters of both drugs are affected when administered in combination. Coadministration of amprenavir with rifabutin results in a 15% decrease in amprenavir plasma AUC and a 200% increase in rifabutin plasma AUC. A dosage reduction of rifabutin to at least 75% of the recommended dose is required when fosamprenavir calcium and ritonavir are coadministered with rifabutin. Further dose reduction may be necessary. A complete blood count should be performed weekly and as clinically indicated in order to monitor for neutropenia in patients receiving fosamprenavir calcium, ritonavir, and rifabutin.
Anticoagulants		
Warfarin		Concentrations of warfarin may be affected. It is recommended that INR (international normalized ratio) be monitored.

Concomitant Class Name: Drug Name	Effect on Concentration of Amprenavir or Concomitant Drug	Clinical Comment
Anticonvulsants		
Carbamazepine Phenobarbital	↓ Amprenavir	Concomitant administration of anticonvulsant agents known to be enzymatic inducers (e.g., phenobarbital, carbamazepine) has not been studied but may lead to a decrease in the plasma concentrations of amprenavir.
Phenytoin	↓ Amprenavir ↑ Amprenavir ↓ Phenytoin	Coadministration of TELZIR® and phenytoin may result in a decrease in the plasma concentrations of amprenavir. The AUC and C _{min} of amprenavir were increased by 20% and 19 % respectively, with C _{max} unchanged when TELZIR® (700 mg twice daily) plus ritonavir (100 mg twice daily) was given concomitantly with phenytoin (300 mg once daily). The AUC, C _{max} and C _{min} of phenytoin were decreased by 22 %, 20 % and 29 % respectively. Plasma concentrations of phenytoin should be monitored and phenytoin dose increased as appropriate. No change to the TELZIR®/ritonavir dosage regimen is required. The TELZIR®/ritonavir once daily regimen has not been studied.
Antidepressants		
Paroxetine	↓ Paroxetine	Plasma concentrations of paroxetine may be significantly decreased when coadministered with TELZIR® and ritonavir. Any paroxetine dose adjustment should be guided by clinical effect (tolerability and efficacy).
Trazodone	↑ Trazodone	Concomitant use of trazodone and TELZIR® with or without ritonavir may increase plasma concentrations of trazodone. Adverse events of nausea, dizziness, hypotension and syncope have been observed following coadministration of trazodone and ritonavir. If trazodone is used with a CYP3A4 inhibitor such as TELZIR®, the combination should be used with caution and a lower dose of trazodone should be considered.
Narcotic Analgesic		
Methadone	↓ Methadone	Co-administration of TELZIR® 700 mg and ritonavir 100 mg twice daily with methadone once daily (≤ 200 mg) for 14 days decreased the active (R-) methadone enantiomer AUC(0-τ) and C _{max} by 18 % and 21 % respectively. The clinical significance of these alterations is unknown; however patients should be monitored for withdrawal syndrome. The impact of co-administration of a once daily regimen of TELZIR® 1200 mg and ritonavir 200 mg on the pharmacokinetics of methadone has not been studied. On the basis of these data no dose adjustment is necessary when TELZIR®/ritonavir is co-administered with methadone.

Concomitant Class Name: Drug Name	Effect on Concentration of Amprenavir or Concomitant Drug	Clinical Comment
Oral contraceptives		
Ethinylestradiol/norethi sterone	↓ Ethinylestradiol ↓ Norethisterone	<p>Co-administration of fosamprenavir with ritonavir and ethinylestradiol/norethisterone resulted in clinically significant hepatic transaminase elevations in some healthy subjects. Co-administration of fosamprenavir 700 mg twice daily + ritonavir 100 mg twice daily with ethinyl estradiol (EE) 0.035 mg/norethisterone (NE) 0.5 mg once daily decreased plasma EE AUC(0-τ) and C_{max} by 37% and 28%, respectively, and decreased plasma NE AUC(0-τ), C_{max}, and Cτ by 34%, 38%, and 26%, respectively.</p> <p>Steady state plasma amprenavir pharmacokinetic parameters were not significantly affected by co-administration with ethinylestradiol/norethisterone; however, ritonavir AUC(0-τ) and C_{max} were 45% and 63% higher, respectively, compared to historical data in female subjects dosed with fosamprenavir / ritonavir alone.</p> <p>Therefore alternative non-hormonal methods of contraception are recommended for women of childbearing potential (see WARNINGS AND PRECAUTIONS section).</p>
Antacids		
Aluminum hydroxide/ Magnesium hydroxide	↓ Amprenavir	<p>The pharmacokinetic parameters of amprenavir are affected when administered in combination. The AUC and C_{max} of amprenavir were decreased by 18% and 35% respectively, while the C_{min} (C12) was increased by 14%, when a single 1400 mg dose of fosamprenavir calcium was coadministered with a single 30 mL dose of antacid suspension (equivalent to 2.75 grams aluminum hydroxide and 1.8 grams magnesium hydroxide).</p> <p>No dose adjustment for any of the respective medicinal products is considered necessary when administered concomitantly.</p>
Benzodiazepines		
Alprazolam Clorazepate Diazepam Flurazepam Midazolam Triazolam	↑ Benzodiazepines	Possible increased benzodiazepine activity. Alprazolam, clorazepate, diazepam, flurazepam, midazolam and triazolam may have their serum concentrations increased by fosamprenavir calcium, which could increase their activity (see CONTRAINDICATIONS section).

Concomitant Class Name: Drug Name	Effect on Concentration of Amprenavir or Concomitant Drug	Clinical Comment
Calcium Channel Blockers		
Diltiazem Amlodipine Nifedipine Felodipine Verapamil Nimodipine	↑ Calcium channel blockers	Possible increased calcium channel blocker activity. Diltiazem, amlodipine, nifedipine, felodipine, verapamil, and nimodipine may have their serum concentrations increased by fosamprenavir calcium, which could increase their activity.
Corticosteroids		
Dexamethasone	↓ Amprenavir	May induce CYP3A4 and decrease plasma concentrations of amprenavir.
PDE5 Inhibitors		
Sildenafil Vardenafil Tadalafil	↑ Sildenafil ↑ Vardenafil ↑ Tadalafil	Coadministration of TELZIR [®] and ritonavir with erectile dysfunction agents is expected to substantially increase PDE5 inhibitor plasma concentrations and may result in PDE5 inhibitor associated adverse events, including hypotension, syncope, visual changes and priapism. Concomitant use of PDE5 inhibitors (e.g., sildenafil, vardenafil or tadalafil) in patients receiving TELZIR [®] is not recommended.
Glucocorticoids		
Fluticasone propionate	↑ Fluticasone	Systemic corticosteroid effects including Cushing's syndrome and adrenal suppression have been reported in patients receiving ritonavir and inhaled or intranasally administered fluticasone propionate; this interaction is also expected with other corticosteroids metabolised via the P450 3A pathway. Concomitant use of fluticasone propionate and ritonavir should be avoided, unless the potential benefit to the patient outweighs the risk of systemic corticosteroid side effects.

Concomitant Class Name: Drug Name	Effect on Concentration of Amprenavir or Concomitant Drug	Clinical Comment
Histamine H2 receptor antagonist		
Cimetidine Ranitidine Famotidine Nizatidine	↓ Amprenavir	<p>The pharmacokinetic parameters of amprenavir are affected when administered in combination. Serum levels of amprenavir can be reduced by concomitant use of histamine H2 receptor antagonists (for example ranitidine and cimetidine). Concurrent administration of ranitidine (300 mg single dose) with fosamprenavir calcium (1400 mg single dose) decreased plasma amprenavir AUC by 30% and C_{max} by 51%. There was, however, no change observed in the amprenavir C_{min} (C12).</p> <p>No dose adjustment for any of the respective medicinal products is considered necessary when administered concomitantly.</p>
HMG-CoA reductase inhibitors		
Atorvastatin Lovastatin Simvastatin	↑ Atorvastatin ↑ Lovastatin ↑ Simvastatin	<p>HMG-CoA reductase inhibitors (statins) may interact with protease inhibitors and increase the risk of myopathy including rhabdomyolysis. Concomitant use of protease inhibitors with lovastatin or simvastatin is not recommended. Other HMG-CoA reductase inhibitors (statins), may also interact with protease inhibitors. Use the lowest possible dose of atorvastatin with careful monitoring or consider the use of pravastatin or fluvastatin as alternative HMG-CoA reductase inhibitors in combination with TELZIR® (see WARNINGS AND PRECAUTIONS section).</p> <p>The C_{max} and AUC of atorvastatin were increased by 304% and 130% respectively and C_{min} was decreased 10% when atorvastatin (10 mg once daily for 4 days) was given with fosamprenavir (1400 mg BID for two weeks). The C_{max}, AUC and C_{min} of amprenavir were decreased 18%, 27% and 12% respectively. When used with fosamprenavir, doses of atorvastatin no greater than 20 mg/dose should be administered with careful monitoring for atorvastatin toxicity. The same recommendation is also made with atorvastatin administered with fosamprenavir and ritonavir.</p>

Concomitant Class Name: Drug Name	Effect on Concentration of Amprenavir or Concomitant Drug	Clinical Comment
Immunosuppressants		
Cyclosporin Rapamycin Tacrolimus	↑ Immunosuppressants	Plasma concentrations of cyclosporin, rapamycin and tacrolimus may be increased when coadministered with fosamprenavir calcium and ritonavir. Therefore, frequent therapeutic concentration monitoring is recommended until levels have stabilized.
Proton pump inhibitors (PPIs)		
Esomeprazole Omeprazole Lansoprazole Pantoprazole Rabeprazole	No effect	Coadministration of esomeprazole with fosamprenavir did not alter plasma amprenavir AUC, C _{max} , or C _{min} ; plasma esomeprazole AUC was increased 55% and t _{max} was delayed 1 hour; while C _{max} was unchanged. Coadministration with fosamprenavir in combination with ritonavir for 14 days did not alter plasma amprenavir AUC, C _{max} , or C _{min} and did not alter plasma esomeprazole AUC or C _{max} ; esomeprazole t _{max} was delayed 1 hour. No dose adjustment is considered necessary when administered concomitantly.
Tricyclic antidepressants		
Amitriptyline Imipramine	↑ Tricyclics	Therapeutic concentration monitoring is recommended for tricyclic antidepressants.

Drug-Food Interactions

Interactions with food have not been established.

Drug-Herb Interactions

Table 8 Established or Potential Drug-Drug Interactions

Proper name	Effect	Clinical comment
St. John's Wort	May result in reduced plasma concentrations of amprenavir.	Patients on TELZIR [®] should not use products containing St. John's Wort (<i>Hypericum perforatum</i>) since it may result in reduced plasma concentrations of amprenavir (see WARNINGS AND PRECAUTIONS section).

Drug-Laboratory Test Interactions

Interactions with laboratory tests have not been established.

DOSAGE AND ADMINISTRATION

A physician experienced in the management of HIV infection should initiate therapy.

Higher than approved dose combinations of TELZIR[®] (fosamprenavir calcium) with ritonavir is not recommended for use (see WARNINGS AND PRECAUTIONS section) due to risk of transaminase elevations.

Recommended Dose and Dosage Adjustment

Once-daily administration of TELZIR[®]/ritonavir combination is not recommended in protease inhibitor-experienced patients or any pediatric patients.

Adults (≥ 18 years of age):

Low doses of ritonavir may be used to enhance the pharmacokinetic profile of amprenavir. Higher than approved dose combinations of fosamprenavir with ritonavir is not recommended for use. The recommended oral dose of fosamprenavir, in combination with ritonavir is outlined below.

Tablets:

Therapy Naïve Patients:

Once Daily: 1400 mg TELZIR[®] and 200 mg ritonavir

Twice Daily: 700 mg TELZIR[®] and 100 mg ritonavir

Protease Inhibitor-Experienced Patients:

Twice Daily: 700 mg TELZIR[®] and 100 mg ritonavir

TELZIR[®] tablets can be taken with or without food.

Oral Suspension:

Therapy Naïve Patients:

Once Daily: 1400 mg TELZIR[®] and 200 mg ritonavir

Twice Daily: 700 mg TELZIR[®] and 100 mg ritonavir

Protease Inhibitor-Experienced Patients:

Twice Daily: 700 mg TELZIR[®] and 100 mg ritonavir

TELZIR[®] oral suspension should be taken by adults without food and on an empty stomach. Shake the bottle vigorously before use.

Pediatric Patients (≥ 6 years old):

The recommended dosage of TELZIR[®] in patients ≥ 6 years of age should be calculated based on body weight (kg) and should not exceed the recommended adult dose. The data in pediatrics are insufficient to recommend: (1) once daily dosing or (2) any dosing in patients < 6 years old.

TELZIR[®] oral suspension is the recommended option for the most accurate dosing based on body weight. Pediatric patients should take oral suspension with food to aid palatability and assist adherence. The dose recommendations for this population are based on studies where the TELZIR[®] oral suspension was administered with ritonavir and with food, and therefore take into account the observed food effect (see DETAILED PHARMACOLOGY). Should vomiting occur within 30 minutes after dosing, the oral suspension should be re-dosed.

Oral Suspension:

Therapy Naive and Protease Inhibitor Experienced:

Twice daily: 18 mg/kg plus ritonavir 3 mg/kg administered twice daily not to exceed the adult dose of 700 mg plus ritonavir 100 mg.

Tablets:

Therapy Naive and Protease Inhibitor Experienced:

Twice daily: not to exceed 700 mg plus ritonavir 100 mg

The adult tablet regimens of TELZIR[®]/ ritonavir may be used in patients who weigh at least 39 kg (ritonavir tablets may be used in patients who weight at least 33kg) and can swallow the tablets whole (see DOSAGE AND ADMINISTRATION: Adults > 18 years of age).

Pediatrics (< 2 years of age):

The safety and efficacy of TELZIR[®] in combination with ritonavir have not yet been established in this patient population.

Geriatrics (≥ 65 years of age):

The safety and efficacy of TELZIR[®] in combination with ritonavir have not yet been established in this patient population.

Patients with Hepatic Impairment

TELZIR[®] and ritonavir should be used with caution and at reduced doses in adults with mild, moderate or severe hepatic impairment (see WARNINGS AND PRECAUTIONS and CLINICAL TRIALS). There are no data on the use of TELZIR[®] with ritonavir in pediatric patients with any degree of hepatic impairment; no dose recommendation can be made in this patient population.

Adults with Mild Hepatic Impairment (Child-Pugh score 5-6)

TELZIR[®] 700 mg twice daily plus ritonavir 100 mg once daily

Adults with Moderate Hepatic Impairment (Child-Pugh score 7-9)

TELZIR[®] 450 mg twice daily plus ritonavir 100 mg once daily

Adults with Severe Hepatic Impairment (Child-Pugh score: 10-15)
TELZIR[®] 300 mg twice daily plus ritonavir 100 mg once daily.

Even with these dose adjustments for adults with hepatic impairment, some subjects may have higher than anticipated amprenavir and ritonavir plasma concentrations due to inter-patient variability. Therefore, appropriate laboratory tests for liver function should be conducted prior to initiating therapy and at periodic intervals during treatment (see WARNINGS AND PRECAUTIONS section).

Although it is not possible to achieve the 300 mg and 450 mg dose using the tablet formulation, they can be obtained with the TELZIR[®] oral suspension.

Patients with Renal Impairment

No initial dose adjustment is considered necessary in patients with renal impairment.

OVERDOSAGE

There is no known antidote for TELZIR[®] (fosamprenavir calcium). It is not known whether amprenavir can be removed by peritoneal dialysis or hemodialysis. If overdosage occurs, the patient should be monitored for evidence of toxicity and standard supportive treatment applied as necessary. Although no data are available, administration of activated charcoal may be used to aid in removal of unabsorbed drug.

For management of a suspected drug overdose, please contact your regional Poison Control Centre.
--

ACTION AND CLINICAL PHARMACOLOGY

Mechanism of Action

Fosamprenavir calcium is a pro-drug of amprenavir, a non-peptidic competitive inhibitor of HIV-1 protease. It blocks the ability of viral protease to process gag and gag-pol polyproteins necessary for viral replication.

Fosamprenavir calcium is rapidly hydrolyzed to amprenavir by enzymes in the gut epithelium as it is absorbed.

Pharmacokinetics

Absorption and Bioavailability

After multiple-dose oral administration of fosamprenavir calcium 1400 mg once daily and ritonavir 200 mg once daily, amprenavir was rapidly absorbed with a geometric mean (95% CI) steady-state peak plasma amprenavir concentration (C_{\max}) of 7.24 (6.32-8.28) $\mu\text{g/mL}$ occurring approximately 2 (0.8-5.0) hours after dosing (t_{\max}). The geometric mean steady-state plasma amprenavir trough concentration (C_{\min}) was 1.45 (1.16-1.81) $\mu\text{g/mL}$ and $\text{AUC}_{24,ss}$ was 69.4 (59.7-80.8) $\text{h}\cdot\mu\text{g/mL}$.

After multiple-dose oral administration of fosamprenavir calcium 700 mg twice daily and ritonavir 100 mg twice daily, amprenavir was rapidly absorbed with a geometric mean (95% CI) steady-state peak plasma amprenavir concentration (C_{\max}) of 6.08 (5.38-6.86) $\mu\text{g/mL}$ occurring approximately 1.5 (0.75-5.0) hours after dosing (t_{\max}). The mean steady-state plasma amprenavir trough concentration (C_{\min}) was 2.12 (1.77-2.54) $\mu\text{g/mL}$ and $\text{AUC}_{24,ss}$ was 79.2 (69.0-90.6) $\text{h}\cdot\mu\text{g/mL}$. The absolute oral bioavailability of amprenavir in humans has not been established.

Fosamprenavir calcium tablet and oral suspension formulations, both given fasted, delivered equivalent plasma amprenavir AUC_{∞} values and the TELZIR[®] oral suspension formulation delivered a 14% higher plasma amprenavir C_{\max} as compared to the oral tablet formulation.

Effects of Food on Oral Absorption

Tablets

The relative bioavailability of fosamprenavir calcium tablets was assessed in the fasted and fed states in healthy volunteers (standardized high-fat meal: 967 kcal, 67 grams fat, 33 grams protein, 58 grams carbohydrate). Administration of a single 1400 mg dose of TELZIR[®] in the fed state compared to the fasted state was associated with no changes in C_{\max} , T_{\max} or $\text{AUC}_{0-\infty}$. TELZIR[®] tablets may be taken with or without food.

Suspension

The administration of fosamprenavir calcium oral suspension formulation with a high-fat meal reduced plasma amprenavir AUC by approximately 28% and C_{\max} by approximately 46% as compared to the administration of this formulation in the fasted state. The TELZIR[®] oral suspension should be taken without food and on an empty stomach at the same dose as the tablets in the adult population; however, with food in the children and adolescent population (see DOSAGE AND ADMINISTRATION section).

Special Populations and Conditions

Pediatrics (≥ 6 years old)

The pharmacokinetics parameters of amprenavir were evaluated in 47 pediatric patients (6 to 18 years old) following administration of TELZIR[®] (oral suspension or tablets), with ritonavir and with food (see Table 9 below).

Table 9 Geometric Mean (95% CI) Steady-State Plasma Amprenavir Pharmacokinetic Parameters in Pediatric Patients (≥ 6 years old) Receiving TELZIR[®] Plus Ritonavir Twice Daily

Parameter	6 to 11 Years		12 to 18 Years	
	n	Fosamprenavir 18 mg/kg plus Ritonavir 3 mg/kg b.i.d.	n	Fosamprenavir 700 mg plus Ritonavir 100 mg b.i.d.
AUC ₍₀₋₂₄₎ (mcg•hr/mL)	9	93.4 (67.8, 129)	8	58.8 (38.8, 89.0)
C _{max} (mcg/mL)	9	6.07 (4.40, 8.38)	8	4.33 (2.82, 6.65)
C _{min} (mcg/mL)	17	2.69 (2.15, 3.36)	24	1.61 (1.21, 2.15)

Geriatrics

The pharmacokinetics of fosamprenavir calcium have not been studied in patients over 65 years of age.

Gender

The pharmacokinetics of fosamprenavir calcium does not differ between males and females.

Hepatic Insufficiency

The pharmacokinetics of amprenavir were studied following the administration of TELZIR[®] and ritonavir for 14 days to HIV-1-infected adults with hepatic impairment and to matched controls with normal hepatic function. Following 2 weeks of dosing with TELZIR[®] plus ritonavir, the AUC of amprenavir was increased by approximately 22% in patients with mild hepatic impairment and by approximately 70% in patients with moderate hepatic impairment compared with HIV-1-infected patients with normal hepatic function. Protein binding of amprenavir was decreased in both mild and moderate hepatic impairment, with the unbound fraction at 2 hours (approximate C_{max}) increasing by 18% to 57% and the unbound fraction at the end of the dosing interval (C_{min}) increasing 50% to 102%. In patients with severe hepatic impairment (Child-Pugh score of 10-13), a reduced dose of TELZIR[®] 300 mg twice daily with a reduced dosing frequency of ritonavir 100 mg once daily delivered 19% lower plasma amprenavir C_{max}, 23% lower AUC (0-τ), and 38% lower Cτ values, but similar unbound plasma amprenavir Cτ values than achieved in patients with normal hepatic function receiving the standard TELZIR[®] with ritonavir 700 mg/100 mg twice daily regimen. Despite reducing the dosing frequency of ritonavir, patients with severe hepatic impairment had 64% higher ritonavir C_{max}, 40% higher ritonavir C_{avg}, and 38% higher ritonavir Cτ than

achieved in patients with normal hepatic function receiving the standard TELZIR[®] with ritonavir 700 mg/100 mg twice daily regimen. The pharmacokinetic parameters for amprenavir are summarized in Table 10 below.

Table 10 Pharmacokinetics of Amprenavir (APV) following the administration of TELZIR[®] and ritonavir for 14 days to HIV-1-infected adults with hepatic impairment vs. adults with normal hepatic function

	Normal Hepatic Function^a (FPV 700 mg BID + RTV 100 mg BID) n=10	Mild Hepatic Impairment (Child Pugh 5-6) (FPV 700 mg BID + RTV 100 mg BID) n=9		Moderate Hepatic Impairment (Child Pugh 7-9) (FPV 300 mg BID + RTV 100 mg QD) n=10		Normal Hepatic Function^b (FPV 700 mg BID + RTV 100 mg BID) n=7		Severe Hepatic Impairment (Child Pugh 10-15) (FPV 300 mg BID + RTV 100 mg QD) n=8
APV Parameter	Parameter Estimate Geometric Mean [95% CI] (CVb%)	Parameter Estimate Geometric Mean [95% CI] (CVb%)	Mild vs Normal^a GLS Mean Ratio [90% CI]	Parameter Estimate Geometric Mean [95% CI] (CVb%)	Moderate vs Normal^a GLS Mean Ratio [90% CI]	Parameter Estimate Geometric Mean [95% CI] (CVb%)	Parameter Estimate Geometric Mean [95% CI] (CVb%)	Severe vs Normal^b GLS Mean Ratio [90% CI]
AUC (0- τ) ($\mu\text{g}\cdot\text{h/mL}$)	38.1[31.6, 46.0] (27)	46.6[39.0, 55.5] (25)	1.22 [0.94, 1.59]	27.8 [19.9, 38.7] (49)	0.73 [0.56, 0.95]	39.4 [34.5, 45.0] (14)	30.3 [22.6, 40.7] (36)	0.77 [0.60, 0.99]
C _{max} ($\mu\text{g/mL}$)	6.00 [4.97, 7.25] (27)	7.04 [5.72, 8.66] (30)	1.17 [0.90, 1.53]	4.38 [3.08, 6.22] (52)	0.73 [0.56, 0.95]	5.94 [5.05, 6.99] (18)	4.80 [3.52, 6.54] (38)	0.81 [0.62, 1.06]
Free Fraction (%) unbound at $\sim\text{C}_{\text{max}}$	7.53 ^c [6.10, 9.29] (28)	8.92 [7.68, 10.4] (21)	1.18 [0.94, 1.50]	10.1 ^c [7.49, 13.5] (40)	1.33 [1.05, 1.69]	8.97 ^e [5.14, 15.7] (57)	8.37 ^f [6.57, 10.7] (27)	0.93 [0.62, 1.40]
C τ ($\mu\text{g/mL}$)	2.62 [2.14, 3.21] (29)	2.38 [1.80, 3.15] (40)	0.91 [0.63, 1.32]	1.13 [0.74, 1.71] (64)	0.43 [0.30, 0.62]	2.19 [1.82, 2.64] (20)	1.36 [0.85, 2.16] (60)	0.62 [0.42, 0.92]
Free Fraction (%) unbound at C τ	6.16 ^c [4.52, 8.38] (42)	10.9 ^d [8.88, 13.3] (25)	1.77 [1.37, 2.27]	12.5 ^c [9.98, 15.5] (29)	2.02 [1.58, 2.58]	5.69 ^g [3.72, 8.69] (35)	9.37 [6.24, 14.1] (52)	1.65 [1.05, 2.58]
<p>a. First normal hepatic function group matched for sex, age (+/-5 years), and BMI (+/-5kg) to subjects with moderate hepatic impairment and compared to subjects with mild and moderate hepatic impairment</p> <p>b. Second normal hepatic function group matched for sex, age (+/-5 years), and BMI (+/-5kg) to subjects with severe hepatic impairment and compared to subjects with severe hepatic impairment</p> <p>c. N=9</p> <p>d. N=8</p> <p>e. N=6</p> <p>f. N=7</p> <p>g. N=5</p>								

Renal Insufficiency

Adults with Impaired Renal Function

The safety and efficacy of TELZIR[®] have not been studied in patients with renal impairment. The renal elimination of unchanged amprenavir represents < 1% of the administered dose. Renal elimination of ritonavir is also negligible; therefore, the impact of renal impairment on amprenavir elimination should be minimal.

STORAGE AND STABILITY

Tablets

TELZIR[®] (fosamprenavir calcium) tablets should be stored between 15°C and 30°C.

Suspension

TELZIR[®] suspension should be stored between 2°C and 30°C. **Do not freeze. The suspension should be discarded 28 days after first opening.**

SPECIAL HANDLING INSTRUCTIONS

Not applicable.

DOSAGE FORMS, COMPOSITION AND PACKAGING

TELZIR[®] (fosamprenavir calcium) tablets, 700 mg, are pink in colour and are capsule-shaped, with the letters "GX LL7" printed on one side of the tablet. TELZIR[®] tablets are available in bottles of 60 tablets per bottle with child-resistant closures.

TELZIR[®] suspension is available in a bottle of 225 mL of 50 mg/mL fosamprenavir calcium oral suspension. The oral suspension is white to off-white in color with grape bubblegum and peppermint flavoring. A 10 mL dosing syringe is provided in the pack.

Composition

Tablets

TELZIR[®] tablets are available for oral administration in a strength of 700 mg of fosamprenavir as fosamprenavir calcium (equivalent to approximately 600 mg of amprenavir). Each 700 mg tablet contains the inactive ingredients colloidal silicon dioxide, croscarmellose sodium, magnesium stearate, microcrystalline cellulose, and povidone K30. The tablet film-coating contains the inactive ingredients hypromellose, iron oxide red, titanium dioxide, and triacetin.

Suspension

TELZIR[®] oral suspension contains 50 mg/mL fosamprenavir as calcium salt (equivalent to approximately 43 mg/mL amprenavir). The oral suspension contains hypromellose, sucralose, propylene glycol, methyl parahydroxybenzoate, propyl parahydroxybenzoate, polysorbate 80, calcium chloride dihydrate, artificial grape bubblegum flavour, natural peppermint flavour, purified water.

PART II: SCIENTIFIC INFORMATION

PHARMACEUTICAL INFORMATION


Drug Substance

Proper name: fosamprenavir calcium

Chemical name: (3S)-tetrahydrofuran-3-yl (1S,2R)-3-[[[4-(aminophenyl) sulphonyl](isobutyl)amino]-1-benzyl-2-(phosphonoxy) propyl]carbamate monocalcium salt

Molecular formula and molecular mass: $C_{25}H_{34}CaN_3O_9PS$ 623.7

Structural formula:



Physicochemical properties:

Description:

Fosamprenavir calcium is a white to cream-coloured solid with a solubility of approximately 0.31 mg/mL in water at 25°C. Fosamprenavir calcium does not melt but decomposes at a temperature of 160°C.

pH

The pH of an aqueous solution of amprenavir at 0.31 mg/mL was determined to be 8.1 at 25°C.

CLINICAL TRIALS

Antiretroviral-Naïve Adult patients

In antiretroviral-naïve patients in APV30002, TELZIR[®] (fosamprenavir calcium) (1400 mg) given once daily in combination with low-dose ritonavir (200 mg) as part of a triple regimen including abacavir (300 mg twice daily) and lamivudine (150 mg twice daily) showed similar efficacy over 48 weeks compared to nelfinavir (1250 mg) given twice daily in combination with abacavir/lamivudine (300 and 150 mg twice daily respectively). In the ITT (Missing or Discontinuation =Failure (MD =F)) analysis, 68% of subjects receiving TELZIR[®]/ritonavir had plasma HIV-1 RNA below 400 copies/mL at week 48 compared to 65% (95% CI [-4 to 10%]) in the nelfinavir arm. In the per protocol analysis the proportion of subjects was respectively 95% and 91% (95% CI [0 to 9%]).

The majority of subjects who had reductions in viral load to < 400 copies/mL also had reductions to < 50 copies/mL (ITT (MD=F): 56% in the TELZIR[®]/ritonavir group vs. 52% in the nelfinavir group (95% CI [-5 to 11%]).

Table 11 Study APV 30002

	TELZIR [®] /ritonavir once daily % (n/N)	Nelfinavir twice daily % (n/N)	Stratified Difference	95% CI
Proportions of subjects with HIV-1 RNA < 400 copies/ml				
ITT(E) MD=F	68 (220/322)	65 (213/327)	3%	-4%, 10%
Per Protocol	95 (215/226)	91 (215/237)	4%	-0%, 9%
Proportions of subjects with HIV-1 RNA < 50 copies/ml				
ITT(E) MD=F	56 (179/322)	52 (171/327)	3%	-5%, 11%
Per Protocol	78 (176/226)	72 (171/237)	6%	-2%, 13%

The median plasma HIV-1 RNA had decreased by 3.1 log₁₀ copies/ml at week 48 in both TELZIR[®]/ritonavir and nelfinavir arms.

The median baseline CD4 cell count was low (170 cells/mm³) in both groups. CD4+ cell counts increased in both the TELZIR[®]/ritonavir and nelfinavir groups, with median increases above baseline being similar in magnitude at Week 48 (+203 and +207 cells/mm³, respectively).

The number of subjects that prematurely discontinued due to virological failure was greater in the nelfinavir arm (15%) of the study as compared to the TELZIR[®]/ritonavir-treated group (4%). In patients experiencing therapy failure from the latter group there was no evidence of the selection by the TELZIR[®]/ritonavir combination of any primary or secondary protease resistance mutations, including those associated with development of resistance to amprenavir or ritonavir. This was in contrast to a high incidence (56%) of the development of primary or secondary protease mutations in the nelfinavir arm.

The frequency of acquisition of mutations associated with resistance to the concomitantly administered NRTI (abacavir, lamivudine) in the TELZIR[®]/ritonavir-treated subjects was low (4/32 (13%)). For the nelfinavir-treated subjects, the incidence of acquisition of mutation was significantly more frequent (31/54 (57%)), $p < 0.001$.

The absence of resistance development and any cross-resistance to other PIs indicates that the failure of a regimen containing TELZIR[®]/ritonavir should not impact susceptibility or response to a subsequent PI-containing regimen.

Protease Inhibitor-Experienced Adult Patients

APV30003 is a randomized open-label study comparing two different regimens of the TELZIR[®]/ritonavir combination with lopinavir/ritonavir in protease inhibitor-experienced patients with virological failure (less than or equal to two PI's). TELZIR[®] given in combination with low-dose ritonavir both once daily (1400 mg/200 mg) or twice daily (700 mg/100 mg) in combination with two active reverse transcriptase inhibitors (NRTIs) showed similar efficacy over 24 weeks compared to the fixed-dose combination of lopinavir/ritonavir (400 mg/100 mg twice daily). All patients in this study had failed treatment with a previous protease inhibitor regimen (defined as plasma HIV-1 RNA that never went below 1,000 copies/ml after at least 12 consecutive weeks of therapy, or initial suppression of HIV-1 RNA which subsequently rebounded to $> 1,000$ copies/mL).

Each treatment group demonstrated viral suppression as measured by the average area under the curve minus baseline (AAUCMB) for plasma HIV-1 RNA viral load over 24 weeks. Mean AAUCMB values (\log_{10} copies/mL) for each group were: -1.48 for once-daily TELZIR[®]/ritonavir, -1.50 for twice-daily TELZIR[®]/ritonavir, and -1.66 for lopinavir/ritonavir. The 2 regimens of TELZIR[®]/ritonavir were comparable to the lopinavir/ritonavir regimen based on AAUCMB.

The TELZIR[®]/ritonavir regimens (once and twice daily) and the lopinavir/ritonavir twice-daily regimen showed similar immunological improvements through 24 weeks of treatment as measured by median change from baseline in CD4+ cell count (TELZIR[®]/ritonavir once daily: 72 cells/mm³; TELZIR[®]/ritonavir twice daily: 62 cells/mm³; lopinavir/ritonavir twice daily: 63 cells/mm³).

Pediatrics

There is no data available in pediatric patients under 2 years old.

Two open label studies were conducted in pediatric patients 2 to 18 years of age. One study (APV29005) evaluated twice daily dosing regimens of TELZIR[®] with ritonavir while the other (APV20003) evaluated once daily dosing of f TELZIR[®] with ritonavir; both studies in combination with other antiretroviral agents. Doses and formulations (TELZIR[®] tablets or oral suspension, ritonavir capsules or oral solution) were determined by patient weight and age. There was insufficient data to support once daily dosing in any pediatric patient population.

Twenty seven protease inhibitor naive and 30 protease inhibitor experienced pediatric patients received either the TELZIR[®] Oral Suspension or Tablets with ritonavir twice daily. At Week 24, 70% of protease inhibitor naive (19/27) and 57% of protease inhibitor experienced (17/30) patients achieved HIV 1 RNA < 400 copies/mL; median increases from baseline in CD4+ cell counts were 131 cells/mm³ and 149 cells/mm³ in protease inhibitor naive and experienced patients, respectively.

DETAILED PHARMACOLOGY

Pharmacokinetics in Adults

Absorption

After multiple-dose oral administration of fosamprenavir calcium 1400 mg once daily and ritonavir 200 mg once daily, amprenavir was rapidly absorbed with a geometric mean (95% CI) steady-state peak plasma amprenavir concentration (C_{max}) of 7.24 (6.32-8.28) micrograms/ml occurring approximately 2 (0.8-5.0) hours after dosing (T_{max}). The mean steady-state plasma amprenavir trough concentration (C_{min}) was 1.45 (1.16-1.81) µg/ml and $AUC_{24,ss}$ was 69.4 (59.7-80.8) h.µg/mL.

After multiple-dose oral administration of fosamprenavir calcium 700 mg twice daily and ritonavir 100 mg twice daily, amprenavir was rapidly absorbed with a geometric mean (95% CI) steady-state peak plasma amprenavir concentration (C_{max}) of 6.08 (5.38-6.86) g/mL occurring approximately 1.5 (0.75-5.0) hours after dosing (T_{max}). The mean steady-state plasma amprenavir trough concentration (C_{min}) was 2.12 (1.77-2.54) µg/mL and $AUC_{24,ss}$ was 79.2 (69.0-90.6) h.µg/mL.

Fosamprenavir calcium tablet and oral suspension formulations, both given fasted, delivered an equivalent plasma amprenavir AUC values and the fosamprenavir calcium oral suspension formulation delivered a 14% higher plasma amprenavir C_{max} as compared to the oral tablet formulation.

The absolute bioavailability of fosamprenavir calcium in humans has not been established.

Tablet

Administration of the fosamprenavir calcium oral tablet formulation (1400 mg) with a high-fat meal did not alter plasma amprenavir pharmacokinetics as compared to the administration of this formulation in the fasted state.

Oral Suspension

Administration of fosamprenavir calcium oral suspension formulation with a high-fat meal reduced plasma amprenavir AUC by approximately 25% and C_{max} by approximately 40% as compared to the administration of this formulation in the fasted state. The fosamprenavir calcium oral suspension should be taken without food at the same dose as the tablets (see DOSAGE AND ADMINISTRATION section).

To aid palatability and assist compliance, the dosing recommendations are to administer the fosamprenavir calcium oral suspension with food in children and adolescents. The dose recommendations for this population were based on the pediatric studies where the TELZIR[®] oral suspension was administered with food, and therefore take into account the observed food effect (see DOSAGE and ADMINISTRATION section).

Table 12 Geometric Mean (95% CI) Steady-State Plasma Amprenavir Pharmacokinetic Parameters

Regimen	C _{max} (µg/mL)	T _{max} (hours) ¹	AUC ₂₄ (µg *hr/mL)	C _{min} (µg /mL)
TELZIR [®] 1400 mg QD plus ritonavir 200 mg QD	7.24 (6.32-8.28)	2.1 (0.8-5.0)	69.4 (59.7-80.8)	1.45 (1.16-1.81)
TELZIR [®] 700 mg BID plus ritonavir 100 mg BID	6.08 (5.38-6.86)	1.5 (0.75-5.0)	79.2 (69.0-90.6)	2.12 (1.77-2.54)

1. Data shown are median (range)

Distribution

The apparent volume of distribution (V_z/F) of amprenavir following administration of TELZIR[®] is approximately 430 litres (6 l/kg assuming a 70 kg body weight), suggesting a large volume of distribution, with penetration of amprenavir freely into tissues beyond the systemic circulation. This value is decreased by approximately 40% when TELZIR[®] is coadministered with ritonavir, most likely due to an increase in amprenavir bioavailability.

Amprenavir is approximately 90% protein bound. It is bound to the alpha-1 acid glycoprotein (AAG) and albumin, but has a higher affinity for AAG.

Metabolism

Fosamprenavir calcium is rapidly and almost completely hydrolyzed to amprenavir and inorganic phosphate as it is absorbed through the gut epithelium, following oral administration. Amprenavir is primarily metabolized by the liver with less than 1% excreted unchanged in the urine. The primary route of metabolism is via the cytochrome P450 3A4 enzyme. Amprenavir metabolism is inhibited by ritonavir, via inhibition of CYP3A4, resulting in increased plasma concentrations of amprenavir. Therefore drugs that are inducers, inhibitors or substrates of CYP3A4 must be used with caution when administered concurrently with TELZIR[®] and ritonavir (see CONTRAINDICATIONS and DRUG INTERACTIONS sections).

Elimination

Following administration of TELZIR[®] the half-life of amprenavir is 7.7 hours. The plasma amprenavir half-life is increased when TELZIR[®] is coadministered with ritonavir.

The primary route of elimination of amprenavir is via hepatic metabolism with less than 1% excreted unchanged in the urine. The metabolites account for approximately 14% of the administered amprenavir dose in the urine, and approximately 75% in the feces.

Special populations

Pediatrics (≥ 6 years old)

The pharmacokinetics parameters of amprenavir were evaluated in 47 pediatric patients (6 to 18 years old) following administration of TELZIR[®] (oral suspension or tablets) with ritonavir and with food.

Table 13 Pharmacokinetic parameters in pediatric and adolescent patients receiving fosamprenavir with ritonavir twice daily

Parameter	6 to 11 Years		12 to 18 Years	
	n	Fosamprenavir 18 mg/kg plus Ritonavir 3 mg/kg Twice daily	n	Fosamprenavir 700 mg plus Ritonavir 100 mg Twice daily
AUC ₍₀₋₂₄₎	9	93.4 (67.8, 129)	8	58.8 (38.8, 89.0)
C _{max} (µg/mL)	9	6.07 (4.40, 8.38)	8	4.33 (2.82, 6.65)
C _τ (µg/mL)	17	2.69 (2.15, 3.36)	24	1.61 (1.21, 2.15)

Effects of Food on Oral Absorption

After oral administration, fosamprenavir calcium is rapidly and almost completely hydrolyzed to amprenavir and inorganic phosphate prior to reaching the systemic circulation. The conversion of fosamprenavir calcium to amprenavir appears to primarily occur in the gut epithelium.

The pharmacokinetic properties of amprenavir following co administration of TELZIR[®] and ritonavir have been evaluated in healthy adult subjects and HIV-infected patients and no substantial differences were observed between these two groups.

Coadministration of ritonavir with TELZIR[®] enhances plasma amprenavir pharmacokinetics primarily through inhibition of amprenavir metabolism, thus achieving plasma amprenavir concentrations above the IC₅₀ values for amprenavir against HIV from patients with various levels of HIV protease inhibitor experience, including PI-naïve and multiple-PI-experienced patients.

TELZIR[®] tablet and oral suspension formulations, both given fasted, delivered equivalent plasma amprenavir AUC_∞ values and the TELZIR[®] oral suspension formulation delivered a 14% higher plasma amprenavir C_{max} as compared to the oral tablet formulation.

MICROBIOLOGY

Mechanism of Action

TELZIR[®] (fosamprenavir calcium) requires metabolism *in vivo* to generate the active moiety, amprenavir. In the absence of *in vivo* metabolism, fosamprenavir calcium has negligible activity in *in vitro* enzymatic and antiviral assays, and therefore such assays are performed using amprenavir. Amprenavir is a competitive inhibitor of the HIV protease. It blocks the ability of the viral protease to cleave the precursor polyproteins necessary for viral replication.

Coadministration of ritonavir with TELZIR[®] increases plasma amprenavir AUC by approximately 2 times and plasma $C_{\tau,ss}$ by 4 to 6 times, compared to values obtained when TELZIR[®] is administered alone. Administration of TELZIR[®]/ritonavir combination regimens (700/100 mg twice daily and 1400/200 mg once daily) result in plasma amprenavir concentrations above the mean IC_{50} values for amprenavir against HIV for patients spanning the range from PI-naïve (mean protein-binding adjusted IC_{50} = 0.146 μ g/mL) to heavily PI-experienced (mean protein-binding adjusted IC_{50} = 0.90 μ g/mL).

Resistance

HIV-1 isolates with a decreased susceptibility to amprenavir have been selected *in vitro* and obtained from patients treated with fosamprenavir calcium. Genotypic analyses of isolates from amprenavir-treated patients showed mutations in the HIV-1 protease gene resulting in amino acid mutations in the p7/p1 and p1/p6 gag and gag-pol polyprotein precursor cleavage sites. Some of these amprenavir resistance-associated mutations have also been detected in HIV-1 isolates from antiretroviral-naïve patients treated with TELZIR[®]. Of these 488 antiretroviral-naïve patients treated with TELZIR[®] or TELZIR[®]/ritonavir, 61 patients (29 receiving TELZIR[®] and 32 receiving TELZIR[®]/ritonavir) with virological failure (plasma HIV-1 RNA > 1,000 copies/mL on 2 occasions on or after Week 12) were genotyped. Five of the 29 antiretroviral-naïve patients (17%) receiving TELZIR[®] without ritonavir in Study APV30001 had evidence of genotypic resistance to amprenavir: I54L/M (n = 2), I54L + L33F (n = 1), V32I + I47V (n = 1), and M46I + I47V (n = 1). No amprenavir-associated mutations were detected in antiretroviral-naïve patients treated with TELZIR[®]/ritonavir in Study APV 30002.

Cross-Resistance

Varying degrees of HIV-1 cross-resistance among protease inhibitors have been observed.

An association between virologic response at 48 weeks (HIV-1 RNA level < 400 copies/mL) and PI-resistant mutations detected in baseline HIV-1 isolates from PI-experienced patients receiving TELZIR[®]/ritonavir twice daily (n = 88), or lopinavir/ritonavir twice daily (n = 85) in Study APV 30003 is shown in Table 14. The majority of subjects have previously received either one (47%) or 2 PIs (36%), most commonly nelfinavir (57%) and indinavir (53%). Out of 102 subjects with baseline phenotypes receiving twice-daily TELZIR[®]/ritonavir, 54% (55) had resistance to at least one PI with 98% (54) of those having resistance to nelfinavir. Out of 97 subjects with

baseline phenotypes in the lopinavir/ritonavir arm, 60% (58) had resistance to at least one PI with 97% (56) of those having resistance to nelfinavir.

Table 14 Responders at Study Week 48 by Presence of Baseline PI Resistance-Associated Mutations*

PI-mutations ⁺	TELZIR [®] /ritonavir b.i.d. (n= 88)	Lopinavir/ritonavir b.i.d. (n= 85)
D30N	21/22 (95%)	17/19 (89%)
N88D/S	20/22 (91%)	12/12 (100%)
L90M	16/31 (52%)	17/29 (59%)
M46I/L	11/22 (50%)	12/24 (50%)
V82A/F/T/S	2/9 (22%)	6/17 (35%)
I54V	2/11 (18%)	6/11 (55%)
I84V	1/6 (17%)	2/5 (40%)

* Results should be interpreted with caution because sub groups were small

⁺ Most patients had >1 PI resistance -associated mutations at baseline

The virologic response based upon baseline phenotype was assessed. Baseline isolates from PI-experienced patients responding to TELZIR[®]/ritonavir twice daily had a median shift in susceptibility to amprenavir relative to a standard wild-type reference starin of 0.7 (range: 0.1 to 5.4, n= 62), and baseline isolates from individuals failing therapy had a median shift in susceptibility of 1.9 (range: 0.2 to 14, n= 29). Because this was a select patient population, these data do not constitute definitive clinical susceptibility break points. Additional data are needed to determine clinically relevant break points for TELZIR[®].

Isolates from 15 of the 20 patients receiving twice-daily TELZIR[®]/ritonavir and experiencing virologic failure/ongoing replication were subjected to genotypic analysis. The following amprenavir resistance-associated mutations were found either alone or in combination: V32I, M46I/L, I47V, I50V, I54L/M and I84V.

TOXICOLOGY

Acute Toxicity

Fosamprenavir (as the calcium salt) has a very low order of acute oral toxicity in mice and rats. The oral maximum non-lethal doses were greater than 71 times the proposed therapeutic dose of 1400 mg (equivalent to 28 mg/kg/day based on a 50 kg human). Fosamprenavir (as the disodium salt) also has a low order of intravenous toxicity.

Microscopic findings following acute intravenous administration were similar in both species and consisted of myocardial changes (fibre degeneration and/or necrosis) and liver changes (hepatocellular hypertrophy, reduced glycogen vacuolation and periportal hepatocellular vacuolation). The myocardial changes were not observed during acute- or repeat-dose toxicity studies with amprenavir, or during oral acute- and repeat-dose studies with TELZIR[®]. Since fosamprenavir calcium is indicated for oral dosing at

relatively lower dosages, it is considered unlikely that these findings would be of significance for the clinical use of fosamprenavir (as the calcium salt).

Long-Term Toxicity

Fosamprenavir calcium has been administered to rats at dose levels of up to 2240 mg/kg/day for 6 months and to dogs at dose levels of up to 337 mg/kg/day for 9 months.

Gastrointestinal effects were seen in both rats (salivation only) and dogs (salivation, vomiting and fecal alterations), throughout all of the repeat-dose studies with fosamprenavir calcium. In dogs, these effects led to dehydration, electrolyte loss and deterioration to moribund condition in a number of animals.

Liver was the primary target organ for fosamprenavir calcium toxicity in laboratory animals. This organ toxicity consisted of increases in serum alanine aminotransferase, aspartate aminotransferase, glutamate dehydrogenase, γ -glutamyltransferase or alkaline phosphatase activity, increased liver weights and microscopic findings, including hepatocyte necrosis. Some of the liver findings may be the result of induction of drug metabolizing enzymes, which in turn contributed to changes in the thyroid gland that were noted in the 4-week rat study.

The No Observable Adverse Effect Level (NOAEL) was generally determined to be equivalent to or lower than the low dose level in the longest duration repeat-dose studies in rats and dogs due to clinical signs (salivation and fecal alterations), clinical pathology changes and microscopic organ changes. Most of these changes were reversible after cessation of dosing. Systemic exposure to fosamprenavir calcium (prodrug) and amprenavir (active form) at the high dose level at the end of the 6-month rat study is equivalent to 61 times and 1.0 times, respectively, the exposure seen in humans at the proposed therapeutic fosamprenavir calcium dose (1400 mg/day with 200 mg/day ritonavir, AUC in humans 0.024 and 83.2 $\mu\text{g}\cdot\text{h}/\text{mL}$, respectively). In dogs, exposure to fosamprenavir calcium and amprenavir at the high dose level at the end of the 9-month study is equivalent to 46 times and 2.5 times the exposure seen in humans.

Carcinogenicity

In long-term carcinogenicity studies, fosamprenavir was administered orally for up to 104 weeks at doses of 250, 400, or 600 mg/kg/day in mice and at doses of 300, 825, or 2250 mg/kg/day in rats. Exposures at these doses were 0.2 to 0.3-fold (mice) and 0.3 to 0.7-fold (rats) those in humans given 1400 mg once daily of fosamprenavir plus 200 mg ritonavir once daily. Exposures in the carcinogenicity studies were 0.1 to 0.3-fold (mice) and 0.3 to 0.6-fold (rats) those in humans given 700 mg of fosamprenavir plus 100 mg ritonavir twice daily. There was an increase in hepatocellular adenomas and hepatocellular carcinomas at all doses in male mice, and in hepatocellular adenomas and thyroid follicular cell adenomas at all doses in male rats and at 835 and 2250 mg/kg/day in female rats. The relevance of the hepatocellular findings in the rodents for humans is uncertain. Repeat dose studies with fosamprenavir in rats produced effects consistent with enzyme induction, which predisposes rats, but not humans, to thyroid neoplasms. In

addition, in rats only there was an increase in interstitial cell hyperplasia at 825 and 2250 mg/kg/day, and an increase in uterine endometrial adenocarcinoma at 2250 mg/kg/day. The incidence of endometrial findings was slightly increased over concurrent controls, but within background range for female rats. The relevance of the uterine endometrial adenocarcinoma findings in rats for humans is uncertain.

Fosamprenavir was not mutagenic or genotoxic in a battery of *in vitro* and *in vivo* assays. These assays included bacterial reverse mutation (Ames), mouse lymphoma, rat micronucleus, and chromosome aberrations in human lymphocytes.

The significance of the observed effects for humans is uncertain. Amprenavir was not mutagenic or genotoxic in a battery of *in vivo* and *in vitro* genetic toxicity assays, including bacterial reverse mutation (Ames Test), mouse lymphoma, rat micronucleus, and chromosome aberration in human peripheral lymphocytes (see TOXICOLOGY, Mutagenicity section).

Mutagenicity

Neither fosamprenavir nor amprenavir increased the gene mutation frequency in prokaryotic (using Ames and the Yahagi-modified Ames tests at concentrations up to 5000 µg/plate) or eukaryotic cells (using the mouse lymphoma L5178Y tk[±] assay at concentrations up to 5000 or 546 µg/mL, respectively) *in vitro*.

There was no evidence that fosamprenavir calcium had any clastogenic activity in an *in vivo* assay (oral rat micronucleus test at doses up to 2990 µg/kg).

Reproduction and Teratology

In a rat fertility study, there was a reduction in gravid uterine weights following administration of 2240 mg/kg/day fosamprenavir calcium to F₀ female rats, likely related to the lower number of ovarian corpora lutea and uterine implantation sites at this dose. There was no effect on pre- and post-implantation loss or mating success, and the incidence of pregnancy was not affected. Relative testes weights were increased at all dose levels but this finding was not accompanied by microscopic changes in the testes or epididymides. Testes weights were unaffected during repeat-dose studies with rats at similar dosages.

In a rat-embryo fetal-development study with fosamprenavir calcium, maternal toxicity (reduced body weight gain and food consumption) was observed at 300 to 2240 mg/kg/day. There was no evidence of adverse effects on embryo fetal development at any dose level.

In a rabbit-embryo fetal-development study, dose-related maternal toxicity (body weight loss, reduced food consumption, mortality and an increased incidence of abortion at 672.8 mg/kg/day) was observed. There was no evidence of adverse effects on embryo fetal development at any dose level.

In a pre- and post-natal development study in rats, reduced body weight in F₁ pups was seen at all dose levels. An increase in mortality was observed in F₁ male and female pups at 2240 mg/kg/day group between Lactation Days 1 to 21. The reduced F₁ body weights were considered at least partly responsible for developmental delays seen at all dose levels, and also were considered contributory to effects on reproductive function in the F₁ generation (prolonged precoital interval and gestation period, and a slight reduction in implantation sites) at 2240 mg/kg/day. There were no effects on F₂ body weight or survival.

Systemic exposure to amprenavir in the rat-fertility and rat- and rabbit-embryo fetal-development studies with fosamprenavir calcium was low and thus no or very low safety margins over clinical exposure were demonstrated. The doses of fosamprenavir calcium used in these studies were limited by maternal toxicity. The lack of clear safety margins for amprenavir precludes extrapolation to the human situation.

Special Toxicity

In young rats, treatment-related mortality was seen at fosamprenavir calcium dose levels > 553 mg/kg/day. A dose level of 300 mg/kg/day resulted in increased AST and ALT levels and increased liver weights. In males, reversible hyaline droplet accumulation in the cortical tubule epithelial cells was noted in male rats at > 100 mg/kg/day. The finding was considered likely due to male rat specific metabolism of α 2u-globulin and is of limited toxicological relevance to humans.

Fosamprenavir calcium was non-toxic in an acute dermal toxicity study in the rat, and was non-irritant to rabbit skin. Fosamprenavir calcium was a slight irritant to the rabbit eye, but showed no potential for antigenicity in the rat or guinea pig, and was not a dermal sensitizer in the guinea pig.

Coadministration of amprenavir with abacavir (a nucleoside reverse transcriptase inhibitor) to rats caused some clinical pathology changes that were most marked at the highest combination dosage, but these were reversible. Ovarian interstitial cell hypertrophy/hyperplasia occurred only in animals dosed with the combination, but this was reversible and follicular maturation was unaffected. Effects on the liver and adrenal cortex were more severe in the combination groups, but showed evidence of reversal once treatment stopped. Other findings were generally consistent with those observed after administration of either drug alone. Coadministration had no apparent effect on systemic exposure to either compound.

REFERENCES

1. Adkins JC, Faulds D, Moyle G, Hughes WT. Amprenavir. *Drugs* 1998; 55(6): 837-44.
2. Agenerase (Amprenavir) Product Monograph. Boehringer Ingelheim (Canada) Ltd; Jul 2006.
3. Baune B, Furlan A, Taburet AM, Farinotti R. Effects of selected antimalarial drugs and inhibitors of cytochrome P-450 3A4 on halofantrine metabolism by human liver microsomes. *Drug Metab Dispos* 1999 May; 27(5): 565-8.
4. Bendele AM. Urologic Syndrome Mouse. In: Jones TC, Mohr U, Hunt RD, editors. *Urinary System*. New York (NY): Springer-Verlag; 1998. p. 456-62.
5. Brown HR, Leininger JR. Alterations of the Uterus. In: Mohr U, Dungworth DL, Capen CC, editors. *Pathobiology of the Aging Rat*. Washington (DC): International Life Sciences Institute; 1992. vol 1p. 377-88.
6. Capen CC. Mechanistic data and risk assessment of selected toxic end points of the thyroid gland. *Toxicol Pathol* 1997 Jan; 25(1): 39-48.
7. Cato A, III, Cavanaugh J, Shi H, Hsu A, Leonard J, Granneman R. The effect of multiple doses of ritonavir on the pharmacokinetics of rifabutin. *Clin Pharmacol Ther* 1998 Apr; 63(4): 414-21.
8. Charbit B, Becquemont L, Lepere B, Peytavin G, Funck-Brentano C. Pharmacokinetic and pharmacodynamic interaction between grapefruit juice and halofantrine. *Clin Pharmacol Ther* 2002 Nov; 72(5): 514-23
9. Davies TF. Interchangeability of levothyroxine preparations. *Am J Med* 1996 Feb; 100(2): 245-7.
10. Decker CJ, Laitinen LM, Bridson GW, Raybuck SA, Tung RD, Chaturvedi PR. Metabolism of amprenavir in liver microsomes: role of CYP3A4 inhibition for drug interactions. *J Pharm Sci* 1998 Jul; 87(7): 803-7.
11. DeSimone JA, Pomerantz RJ, Babinchak TJ. Inflammatory reactions in HIV-1-infected persons after initiation of highly active antiretroviral therapy. *Ann Intern Med* 2000 Sep 19; 133(6): 447-54.
12. Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. *Clin Pharmacokinet* 2000 Jan; 38(1): 41-57.

13. EuroHIV (2006) HIV/AIDS Surveillance in Europe: Mid-year report 2005. European Commission. [Online] [cited] Saint-Maurice, France. Report 72. Available from: URL: http://www.eurohiv.org/reports/index_reports_eng.htm.
14. Fung HB, Kirschenbaum HL, Hameed R. Amprenavir: a new human immunodeficiency virus type 1 protease inhibitor. *Clin Ther* 2000 May; 22(5): 549-72.
15. Gortmaker SL, Hughes M, Cervia J, Brady M, Johnson GM, Seage GR, III, et al. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. *N Engl J Med* 2001 Nov 22; 345(21): 1522-8.
16. Hirsch HH, Kaufmann G, Sendi P, Battegay M. Immune reconstitution in HIV-infected patients. *Clin Infect Dis* 2004 Apr 15; 38(8): 1159-66..
17. UNAIDS. 2006 report on the global AIDS epidemic: Executive summary. UNAIDS 10th anniversary special ed. United Nations Programme on HIV/AIDS, Switzerland; 2006.
18. Kaletra (Lopinavir/Ritonavir) Product Monograph. Abbott Laboratories, Ltd; Aug 2006.
19. Livingston DJ, Pazhanisamy S, Porter DJ, Partaledis JA, Tung RD, Painter GR. Weak binding of VX-478 to human plasma proteins and implications for anti-human immunodeficiency virus therapy. *J Infect Dis* 1995 Nov; 172(5): 1238-45.
20. Mirmirani P, Maurer TA, Herndier B, McGrath M, Weinstein MD, Berger TG. Sarcoidosis in a patient with AIDS: a manifestation of immune restoration syndrome. *J Am Acad Dermatol* 1999 Aug; 41(2 Pt 2): 285-6.
21. Nachman SA, Stanley K, Yogev R, Pelton S, Wiznia A, Lee S, et al. Nucleoside analogs plus ritonavir in stable antiretroviral therapy-experienced HIV-infected children: a randomized controlled trial. Pediatric AIDS Clinical Trials Group 338 Study Team. *JAMA* 2000 Jan 26; 283(4): 492-8.
22. Nagaoka T, Onodera H, Matsushima Y, Todate A, Shibutani M, Ogasawara H, et al. Spontaneous uterine adenocarcinomas in aged rats and their relation to endocrine imbalance. *J Cancer Res Clin Oncol* 1990; 116(6): 623-8.
23. Norvir (Ritonavir) Product Monograph. Abbott Laboratories, Ltd; Aug 2006.
24. Painter GR, Ching S, Reynolds D, St. Clair B, Elkins M, Blum R, et al. 141W94. Anti-HIV. *Drugs Future* 1996; 21(4): 347-50.

25. Pazhanisamy S, Partaledis JA, Rao BG, Livingston DJ. In vitro selection and characterization of VX-478 resistant HIV-1 variants. *Adv Exp Med Biol* 1998; 436: 75-83.
26. Perez-Elias MJ, Larousse Morellon M, Ortega E, Hernandez-Quero J, Rodriques-Torres M, Clotet B, et al. Pharmacokinetics of Fosamprenavir plus Ritonavir in HIV-1 infected Adult Subjects with Hepatic Impairment. [Manuscript submitted for publication, May 11, 2009].
27. Physician's Desk Reference. 60th ed. Montvale (NJ): Thomson Healthcare; 2006. VIRACEPT® (nelfinavir mesylate) Product Information; p. 2556-7.
28. Polk RE, Brophy DF, Israel DS, Patron R, Sadler BM, Chittick GE, et al. Pharmacokinetic Interaction between amprenavir and rifabutin or rifampin in healthy males. *Antimicrob Agents Chemother* 2001 Feb; 45(2): 502-8.
29. Ramos A, Asensio A, Perales I, Montero MC, Martin T. Prolonged paradoxical reaction of tuberculosis in an HIV-infected patient after initiation of highly active antiretroviral therapy. *Eur J Clin Microbiol Infect Dis* 2003 Jun; 22(6): 374-6.
30. Saez-Llorens X, Violarì A, Deetz CO, Rode RA, Gomez P, Handelsman E, et al. Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children. *Pediatr Infect Dis J* 2003 Mar; 22(3): 216-24.
31. Safdar A, Rubocki RJ, Horvath JA, Narayan KK, Waldron RL. Fatal immune restoration disease in human immunodeficiency virus type 1-infected patients with progressive multifocal leukoencephalopathy: impact of antiretroviral therapy-associated immune reconstitution. *Clin Infect Dis* 2002 Nov 15; 35(10): 1250-7.
32. Salama C, Policar M, Venkataraman M. Isolated pulmonary Mycobacterium avium complex infection in patients with human immunodeficiency virus infection: case reports and literature review. *Clin Infect Dis* 2003 Aug 1; 37(3): 374-76.
33. Sharland M, Blanche S, Castelli G, Ramos J, Gibb DM. PENTA guidelines for the use of antiretroviral therapy, 2004. *HIV Med* 2004 Jul; 5 Suppl 2: 61-86.
34. Shelburne SA, III, Hamill RJ, Rodriguez-Barradas MC, Greenberg SB, Atmar RL, Musher DW, et al. Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy. *Medicine (Baltimore)* 2002 May; 81(3): 213-27.

35. Singh R, Chang SY, Taylor LC. In vitro metabolism of a potent HIV-protease inhibitor (141W94) using rat, monkey and human liver S9. *Rapid Commun Mass Spectrom* 1996; 10(9): 1019-26.
36. St Clair MH, Millard J, Rooney J, Tisdale M, Parry N, Sadler BM, et al. In vitro antiviral activity of 141W94 (VX-478) in combination with other antiretroviral agents. *Antiviral Res* 1996 Jan; 29(1): 53-6.
37. Sustive (Efavirenz) Product Monograph. Bristol-Myers Squibb; Sept 2006.
38. Thaker H, Ong EL. Localized Mycobacterium avium complex infection in a patient on HAART. *Clin Microbiol Infect* 2000 Oct; 6(10): 564-6.
39. The French ANRS (National Agency for AIDS Research) AC11 Resistance Group, HIV-1 genotypic drug resistance interpretation algorithms, Tables of rules, 2006, Protease inhibitors. [Online] [cited 2006 Sep 3] Available from: URL: <http://www.hivfrenchresistance.org/2006/tab2.html> (Available upon request).
40. The Monogram Team, PhenosenseGT™ HIV, PhenosenseGT™ HIV Report Form. [Online] [cited 2006 Sep 3] Available from: URL: <http://www.monogramhiv.com/pdf/PSGT-Sample-Report-2006.pdf> (Available upon request).
41. Tisdale M, Myers RE, Maschera B, Parry NR, Oliver NM, Blair ED. Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors. *Antimicrob Agents Chemother* 1995 Aug; 39(8): 1704-10.
42. Tisdale M, Myers R, Randall S, Maguire M, Ait-Khaled M, Elston R, et al. Resistance to the HIV protease inhibitor amprenavir in vitro and in clinical studies. A review. *Clin Drug Invest* 2000 Oct; 20(4): 267-85.
43. Trevenzoli M, Cattelan AM, Marino F, Marchioro U, Cadrobbi P. Sarcoidosis and HIV infection: a case report and a review of the literature. *Postgrad Med J* 2003 Sep; 79(935): 535-8.
44. Viramune (Nevirapine) Product Monograph. Boehringer Ingelheim (Canada) Ltd; Sept 2006.
45. Walsh KM, Poteracki J. Spontaneous neoplasms in control Wistar rats. *Fundam Appl Toxicol* 1994 Jan; 22(1): 65-72.

PART III: CONSUMER INFORMATION

PrTELZIR®
fosamprenavir calcium tablet
700 mg fosamprenavir

fosamprenavir calcium oral suspension
50 mg/mL fosamprenavir

This leaflet is part III of a three-part "Product Monograph" published when TELZIR® was approved for sale in Canada and is designed specifically for Consumers. This leaflet is a summary and will not tell you everything about TELZIR®. Please read this leaflet carefully before you start to take TELZIR®. Contact your doctor or pharmacist if you have any questions about the drug.

ABOUT THIS MEDICATION**What the medication is used for:**

The name of your medicine is TELZIR® (fosamprenavir calcium). TELZIR® can only be obtained with a prescription from your doctor. TELZIR® is an antiretroviral medication. It is used together with other antiviral medicines to delay the progression of HIV infection in adults and pediatrics of 6 years of age and above.

TELZIR® is to be taken in combination with ritonavir. It is therefore important that you carefully read the Consumer Information Leaflet that is provided with that medicine. If you have any further questions about ritonavir please ask your doctor or pharmacist.

What it does:

The Human Immunodeficiency Virus (HIV) is a retrovirus. Infection with HIV damages the immune system and can lead to Acquired Immune Deficiency Syndrome (AIDS) and other related illnesses.

TELZIR® is an antiretroviral medication. It belongs to a group of medicines called protease inhibitors. TELZIR® in combination with other antiretroviral agents reduces the amount of HIV in your blood. Response to treatment with TELZIR® varies among patients. Your doctor will be monitoring the effectiveness of your treatment. TELZIR® does not cure AIDS or kill the virus, but may help to prevent further damage to the immune system by slowing the production of new viruses.

When it should not be used:

Do not use TELZIR® if:

- You are allergic to ritonavir, fosamprenavir calcium, amprenavir or any of the other ingredients found in TELZIR® or ritonavir (See What the important nonmedicinal ingredients are).
- You are taking any of the following medications with TELZIR® because serious or life-threatening problems could occur: astemizole*, cisapride*, terfenadine* (*no longer

marketed in Canada), diazepam, ergot medications, flurazepam, midazolam, pimozide, triazolam, flecainide, and propafenone.

- **Do not** take rifampin with TELZIR® because this drug reduces the effectiveness of TELZIR®.

What the medicinal ingredient is:

TELZIR® tablets are available for oral administration in a strength of 700 mg of fosamprenavir as fosamprenavir calcium (equivalent to approximately 600 mg of amprenavir).

TELZIR® oral suspension contains 50 mg/mL fosamprenavir as calcium salt (equivalent to approximately 43 mg/mL amprenavir).

What the important nonmedicinal ingredients are:

Each 700 mg tablet contains the inactive ingredients colloidal silicon dioxide, croscarmellose sodium, magnesium stearate, microcrystalline cellulose, and povidone K30. The tablet film-coating contains the inactive ingredients hypromellose, iron oxide red, titanium dioxide, and triacetin.

The oral suspension contains hypromellose, sucralose, propylene glycol, methyl parahydroxybenzoate, propyl parahydroxybenzoate, polysorbate 80, calcium chloride dihydrate, artificial grape bubblegum flavour, natural peppermint flavour and purified water.

What dosage forms it comes in:

TELZIR® tablets, 700 mg, are available in bottles of 60 tablets.

TELZIR® suspension is available in a bottle of 225 mL of 50 mg/mL fosamprenavir calcium oral suspension.

WARNINGS AND PRECAUTIONS

Tell your doctor, before using TELZIR® if:

- You are pregnant or planning to become pregnant. The safe use of TELZIR® in pregnancy has not been determined. Your doctor will provide advice on whether you should use TELZIR®.
- You are breastfeeding. The active substance in TELZIR® is likely to be found in human breast milk and there is no safety data available following treatment with TELZIR® in babies.
- You have any medical conditions, including liver disease, hepatitis, as the amount of medicine you are taking may change.

- You have hemophilia. There have been reports of increased bleeding in patients with hemophilia taking protease inhibitors.
- You are taking oral contraceptives, as TELZIR[®] may be harmful to your liver and may decrease the therapeutic effect of the oral contraceptive. Therefore, alternative non-hormonal methods of contraception (e.g. a condom) are recommended to prevent pregnancy while you are taking TELZIR[®].
- You are using estrogens and /or progestogens as hormone replacement therapy. No data is available on the use of TELZIR[®] with estrogens and/or progestogens as hormone replacement therapy (HRT) for post menopausal women.
- You are allergic to sulfonamide drugs.
- You are taking or planning to take any other drug(s), including those available without a prescription, and herbal medicines such as St. John's Wort (*Hypericum perforatum*). Taking this herb may reduce the effectiveness of TELZIR[®].

Special warnings:

TELZIR[®] oral solution contains propyl and methyl parahydroxybenzoate. These products may cause an allergic reaction in some individuals. This reaction may be delayed.

TELZIR[®] helps to control the amount of HIV found in your blood but is not a cure for HIV infection. You will need to take TELZIR[®] every day. Do not stop taking TELZIR[®] without first talking to your doctor.

HIV is usually spread by sexual contact, blood transfer or by contaminated needles. The risk of spreading HIV still exists during TELZIR[®] therapy; thus, the practice of 'safe sex' and avoidance of sharing needles is necessary.

You may continue to develop other infections and other illnesses associated with HIV disease. You should therefore keep in regular contact with your doctor while taking TELZIR[®].

Mothers with HIV should not breastfeed their infants because HIV in the breastmilk can infect the infant.

Driving and operating machinery

There is no information currently available that suggests taking TELZIR[®] affects the ability to drive or operate machinery.

INTERACTIONS WITH THIS MEDICATION

Some drugs may change the usefulness and safety of TELZIR[®]. It is important that you tell your doctor about all the medicines you are taking or planning to take, including all those that you have bought yourself. This is very important, as using more than one medicine at the same time can strengthen or weaken the effect of the medicine, causing in some cases serious medical conditions. TELZIR[®] may interact with other medicines you are being treated with. Some of the medicines that can interact with amprenavir include: amiodarone, phenobarbital, phenytoin, lidocaine (systemic), tricyclic antidepressants, warfarin, PDE5 inhibitors (e.g. sildenafil, vardenafil, tadalafil), cholesterol-lowering drugs (statins) (e.g. lovastatin, simvastatin), anticonvulsants (e.g. carbamazepine), anti-inflammatory drugs (e.g. dexamethasone), anti-malarial drugs (e.g. halofantrine), quinidine, fluticasone, paroxetine, trazodone, methadone, itraconazole, ketoconazole and immunosuppressants (e.g. cyclosporine, rapamycin and tacrolimus).

PROPER USE OF THIS MEDICATION

Both regimens must be administered in combination with other antiretroviral agents.

Once-daily administration of TELZIR[®]/ritonavir combination is not recommended in protease inhibitor-experienced patients.

The twice-daily plus ritonavir dose is supported by pharmacokinetic and safety data.

Take TELZIR[®] tablets as your doctor has advised you. Take TELZIR[®] oral suspension as your doctor has advised you.

Adults (≥18 years of age):

Low doses of ritonavir may be used to enhance the pharmacokinetic profile of amprenavir. The recommended oral dose of fosamprenavir, in combination with ritonavir is outlined below:

Tablets:

Therapy Naïve Patients:

Once Daily: 1400 mg TELZIR[®] and 200 mg ritonavir
Twice Daily: 700 mg TELZIR[®] and 100 mg ritonavir

Protease Inhibitor-Experienced Patients:

Twice Daily: 700 mg TELZIR® and 100 mg ritonavir

TELZIR® tablets can be taken with or without food.

Oral Suspension:

Therapy Naïve Patients:

Once Daily: 1400 mg TELZIR® and 200 mg ritonavir

Twice Daily: 700 mg TELZIR® and 100 mg ritonavir

Protease Inhibitor-Experienced Patients:

Twice Daily: 700 mg TELZIR® and 100 mg ritonavir

TELZIR® oral suspension should be taken by adults without food and on an empty stomach. Shake the bottle vigorously before use.

Pediatric Patients (≥6 years old):

Pediatric patients should take this oral suspension with food to aid in taste and better encourage compliance with dosing. If vomiting occurs within 30 minutes of dose, the oral suspension dose should be taken again.

Oral Suspension:

Therapy Naïve and Protease Inhibitor Experienced:

Twice daily: 18 mg/kg plus ritonavir 3 mg/kg administered twice daily not to exceed the adult dose of 700 mg plus ritonavir 100 mg.

Tablets:

Therapy Naïve and Protease Inhibitor Experienced:

Twice daily: not to exceed 700 mg plus ritonavir 100 mg

The adult tablet regimens of TELZIR®/ ritonavir may be used in patients who weigh at least 39 kg (ritonavir tablets may be used in patients who weigh at least 33 kg) and can swallow the tablets whole.

The use of TELZIR® has not been studied in pediatric patients below the age of 2.

If you have a liver problem, your dose may be altered. Please follow the instructions of your doctor.

Overdose:

In case of drug overdose, contact a health care practitioner, hospital emergency department or regional Poison Control Centre immediately, even if there are no symptoms.

Missed Dose:

If you forget to take TELZIR®, take it as soon as you remember. Then continue as before. Do not double dose.

SIDE EFFECTS AND WHAT TO DO ABOUT THEM

The following undesirable effects are thought to be related to treatment with TELZIR®: feeling sick, diarrhea, tiredness, headache, abdominal pain, passing gas, rash, kidney stones, higher amounts of a type of fat in the blood and vomiting, and tingling or numbness around lips and mouth.

Changes in body fat have been seen in some patients taking antiretroviral therapy. These changes include increased amounts of fat in the upper back and neck (“buffalo hump”), breasts and around the trunk. Loss of fat from the legs, arms and face may also happen. The cause and long-term health effects of these conditions are not known at this time.

Your doctor will test your blood regularly for increases in blood lipids (blood fat). These have been reported in patients taking TELZIR®, which may lead to an increased risk of a heart attack. Heart attacks have occurred in some patients taking TELZIR®. Increases in liver enzymes have also been reported. Your blood will also be checked for increases in blood sugar levels, as occasionally protease inhibitors have been shown to cause this.

Always tell your doctor or pharmacist about any undesirable effects, even those not mentioned in this leaflet. If you feel ill in any other way that you do not understand, tell your doctor or pharmacist.

SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM

Frequency	Symptom / effect	Talk with your doctor or pharmacist	Stop taking drug and call your doctor or pharmacist
Very Common	Hypercholesterolemia (high blood levels of fat called cholesterol)	✓	
Common	Nausea, vomiting and hypertriglyceridemia (high blood levels of fat called triglycerides).	✓	
Uncommon	Severe life-threatening rash.		✓

SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM

Frequency	Symptom / effect	Talk with your doctor or pharmacist	Stop taking drug and call your doctor or pharmacist
	New or worsening diabetes has been reported with the use of protease inhibitors.	✓	
	Increase in spontaneous bleeding among hemophiliacs using protease inhibitors has been reported.	✓	
	Kidney stones	✓	
Rare	Increase in muscle wasting (rhabdomyolysis), muscle pain has been reported with protease inhibitors.	✓	
	Stevens-Johnson syndrome, angioedema (swelling of the blood vessels and surrounding tissue).		✓

If you have a severe skin rash, check with your doctor as he may advise you to stop taking TELZIR®.

This is not a complete list of side effects. For any unexpected effects while taking TELZIR®, contact your doctor or pharmacist.

HOW TO STORE IT

Store TELZIR® tablets between 15°C and 30°C.

Store TELZIR® suspension between 2°C and 30°C. Do not freeze. Discard the suspension 28 days after first opening. Do not take TELZIR® after the expiry date on the container.

As with all medications, keep TELZIR® out of reach of children.

REPORTING SUSPECTED SIDE EFFECTS

You can report any suspected adverse reactions associated with the use of health products to the Canada Vigilance Program by one of the following 3 ways:

- Report online at www.healthcanada.gc.ca/medeffect
- Call toll-free at 1-866-234-2345
- Complete a Canada Vigilance Reporting Form and:
 - Fax toll-free to 1-866-678-6789, or
 - Mail to: Canada Vigilance Program
Health Canada
Postal Locator 0701E
Ottawa, ON K1A 0K9

Postage paid labels, Canada Vigilance Reporting Form and the adverse reaction reporting guidelines are available on the MedEffect™ Canada Web site at www.healthcanada.gc.ca/medeffect.

NOTE: Should you require information related to the management of side effects, contact your health professional. The Canada Vigilance Program does not provide medical advice.

MORE INFORMATION

Remember: TELZIR[®] is for you. Never give it to someone else. It may harm them even if their symptoms are the same as yours.

This leaflet does not tell you everything about TELZIR[®]. If you have any questions or are not sure about anything, then ask your doctor or pharmacist. You may need to read this leaflet again. Please do not throw this leaflet away until you are no longer taking TELZIR[®].

This document plus the full product monograph, prepared for health professionals can be found at:

www.viivhealthcare.com

or by contacting the sponsor, ViiV Healthcare ULC at:
8455 route Transcanadienne
Montréal, Quebec
H4S 1Z1
1-877-393-8448

This leaflet was prepared by ViiV Healthcare ULC.

Last revised: May 17, 2010

©2010 ViiV Healthcare ULC. All Rights Reserved.

[®]TELZIR is a registered trademark used under license by ViiV Healthcare ULC.

*ViiV Healthcare and the ViiV Healthcare logo are trademarks used under license by ViiV Healthcare ULC.